<SEC-DOCUMENT>0001140361-23-035866.txt : 20230724
<SEC-HEADER>0001140361-23-035866.hdr.sgml : 20230724
<ACCEPTANCE-DATETIME>20230724164044
ACCESSION NUMBER:		0001140361-23-035866
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20230724
DATE AS OF CHANGE:		20230724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273395
		FILM NUMBER:		231105502

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ny20009756x1_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="ny20009756x1_s3_200-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 25pt; text-align: center;">As filed with the Securities and Exchange Commission on July&#160;24, 2023 </div><div class="regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 1pt; text-align: right;">Registration No. 333-&#8195;&#8195;<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt;">Washington, D.C. 20549</font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">FORM S-3<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt;">REGISTRATION STATEMENT </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt;">UNDER </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt;">THE SECURITIES ACT OF 1933</font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">CATALYST BIOSCIENCES, INC.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt; font-weight: normal;">(Exact name of registrant as specified in its charter) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware<font style="font-weight: normal;"> </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(State or other jurisdiction of </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">incorporation or organization)</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">56-2020050<font style="font-weight: normal;"> </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(I.R.S. Employer </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">Identification Number)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">611 Gateway Blvd<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Suite 120<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">South San Francisco, CA 94080<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(650) 871-0761<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">Nassim Usman, Ph.D.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">President and Chief Executive Officer<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">611 Gateway Blvd<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Suite 120<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">South San Francisco, CA 94080<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(650) 871-0761<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">Copies to: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 1pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stephen Thau <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">David Schwartz <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Orrick, Herrington &amp; Sutcliffe LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">51 West 52nd Street <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">New York, NY 10019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(212) 506-5000</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ryan A. Murr <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Branden C. Berns <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gibson, Dunn &amp; Crutcher LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">555 Mission Street, Suite 3000 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">San Francisco, CA 94105 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(415) 393-8200</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 2pt; margin-left: 0pt; text-align: justify;">Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">becomes effective.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If the only securities being registered on this Form&#160;are being offered pursuant to dividend or interest reinvestment plans, please check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If any of the securities being registered on this Form&#160;are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. &#x2612;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If this Form&#160;is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If this Form&#160;is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 22.22%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 22.22%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 22.22%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-accelerated filer &#x2612;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 26.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div></td></tr><tr><td style="width: 22.22%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 22.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 22.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 26.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company &#x2612;</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.<font style="font-weight: normal;"> </font></div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 528pt;"><a name="ny20009756x1_s3_201-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 528pt; margin-left: 0pt;"><div class="h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><div style="font-family: Arial, Helvetica, sans-serif; text-align: left; margin-bottom: 12pt;">The information in this preliminary prospectus is not complete and may be changed. The Selling Stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </div>SUBJECT TO COMPLETION, DATED JULY&#160;24, 2023<font style="color: #000000;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Prospectus</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.25pt; text-align: center;"><img style="height: 75px; width: 236px;" src="logo_catalystbiox2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">1,240,442,745 Shares<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">COMMON STOCK<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">Offered by the Selling Stockholders<font style="font-weight: normal;"> </font></div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 5.5pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus relates to the potential resale from time to time by the Selling Stockholders (as defined below) of up to 1,240,442,745 shares of common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;), including 123,400,000 shares of Common Stock issuable upon the conversion of the Company&#8217;s Series&#160;X Convertible Preferred Stock, par value $0.001 per share (&#8220;Convertible Preferred Stock&#8221;). The &#8220;Selling Stockholders&#8221; refer to GNI USA (as defined below), the Minority Holders (as defined below) and their respective permitted transferees. The shares of Common Stock registered by this prospectus are referred to herein as the &#8220;Resale Shares.&#8221; The Resale Shares consist of: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; text-align: justify;">6,266,521 shares of Common Stock beneficially owned by GNI USA, Inc., a Delaware corporation (&#8220;GNI USA&#8221;), previously issued to GNI Group Ltd. and GNI Hong Kong Limited in a private issuance pursuant to the Asset Purchase Agreement, dated December&#160;26, 2022 (the &#8220;F351 Agreement&#8221;), and transferred to GNI USA prior to the closing of the transactions contemplated by the Business Combination Agreement (as defined below); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; text-align: justify;">123,400,000 shares of Common Stock issuable upon conversion of 12,340 shares of Convertible Preferred Stock beneficially owned by GNI USA, previously issued to GNI Group Ltd. and GNI Hong Kong Limited in the private issuance pursuant to the F351 Agreement, and transferred to GNI USA prior to the closing of the transactions contemplated by the Business Combination Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; text-align: justify;">953,821,796 shares of Common Stock issuable to GNI USA pursuant to the Business Combination Agreement, dated December&#160;26, 2022 (the &#8220;Business Combination Agreement&#8221;), by and among the Company, GNI USA, the individuals listed on Annex&#160;A thereto (the &#8220;Minority Holders&#8221;) and other parties thereto; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">(iv)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; text-align: left;">156,954,428 shares of Common Stock to be issued to the Minority Holders pursuant to the Business Combination Agreement. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Certain Resale Shares will be issued upon the completion of the transactions contemplated by the Business Combination Agreement (the &#8220;Transactions&#8221;), subject to stockholder approval at the special meeting of stockholders of the Company, which will be held on August 29, 2023, at 8:00 am Pacific Time, unless postponed or adjourned to a later date (the &#8220;Special Meeting&#8221;). We will not seek the effectiveness of the registration statement of which this prospectus forms a part until such stockholder approval is obtained at the Special Meeting. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Further, at the Special Meeting, among other things, we are asking the stockholders of the Company to adopt and approve an amendment to the restated certificate of incorporation of the Company to effect a reverse stock split of Common Stock, by a ratio of not less than 1-for-10 and not more than 1-for-60. In the event the reverse stock split proposal is approved at the Special Meeting and all other conditions precedent to the completion of the Transactions are met or waived, we will file a prospectus supplement or an amendment to the registration statement of which this prospectus is a part, as applicable, to decrease the number of the Resale Shares by giving effect to the reverse stock split. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are not offering or selling any shares of Common Stock under this prospectus, and we will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholders pursuant to this prospectus. Our registration of the securities covered by this prospectus does not mean that the Selling Stockholders will offer or sell any of the Resale Shares. The Selling Stockholders may sell the Resale Shares covered by this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Stockholders may sell the Resale Shares in the section entitled &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If any underwriters, dealers or agents are involved in the sale of any of the Resale Shares, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in an applicable prospectus supplement. See the sections of this prospectus entitled &#8220;<font style="font-style: italic;">About this Prospectus</font>&#8221; and &#8220;<font style="font-style: italic;">Plan of </font><font style="font-style: italic;">Distribution</font>&#8221; for more information. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our Common Stock is currently listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;CBIO.&#8221; We have applied to continue the listing of our Common Stock on Nasdaq under the symbol &#8220;GYRE&#8221; upon the completion of the Transactions. It is a condition to the completion of the Transactions that the Resale Shares be approved for listing on Nasdaq (subject only to official notice of issuance thereof), but there can be no assurance that such listing condition will be met. If such listing condition is not met, the Transactions will not be consummated unless the listing condition is waived pursuant to the terms of the Business Combination Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 4.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On July&#160;21, 2023, the last reported sale price of our Common Stock as reported on Nasdaq was $0.43 per share. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; font-weight: bold; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Investing in our Common Stock involves risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRFS">9</a> of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; font-weight: bold; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 4pt; text-align: center;">The date of this prospectus is July&#160;24, 2023. </div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_202-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page</div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP">About this Prospectus<font style="padding-left: 0.08pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tATP"><font style="padding-left: 9.99pt;">1</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCNR">Cautionary Note Regarding Forward-Looking Statements<font style="padding-left: 0.68pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tCNR"><font style="padding-left: 9.99pt;">2</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">Where You Can Find More Information<font style="padding-left: 1.49pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tWYC"><font style="padding-left: 9.99pt;">4</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIIB">Information Incorporated by Reference<font style="padding-left: 0.13pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tIIB"><font style="padding-left: 9.99pt;">5</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSY">Prospectus Summary<font style="padding-left: 3.97pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tPSY"><font style="padding-left: 9.99pt;">6</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTO">The Offering<font style="padding-left: 1.37pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tTO"><font style="padding-left: 9.99pt;">8</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRFS">Risk Factors<font style="padding-left: 3.41pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tRFS"><font style="padding-left: 9.99pt;">9</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP">Use of Proceeds<font style="padding-left: 2.87pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tUOP"><font style="padding-left: 4.99pt;">10</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSSS">Selling Stockholders<font style="padding-left: 0.63pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tSSS"><font style="padding-left: 5.36pt;">11</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">Plan of Distribution<font style="padding-left: 3.41pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tPOD"><font style="padding-left: 4.99pt;">13</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDPY">Dividend Policy<font style="padding-left: 3.4pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tDPY"><font style="padding-left: 4.99pt;">15</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLMS">Legal Matters<font style="padding-left: 2.86pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tLMS"><font style="padding-left: 4.99pt;">16</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEX">Experts<font style="padding-left: 3.95pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tEX"><font style="padding-left: 4.99pt;">17</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPART2">Part II Information Not Required In Prospectus<font style="padding-left: 0.69pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tPART2">II-1</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSI">Signatures<font style="padding-left: 2.29pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tSI">II-6</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_203-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus is part of the registration statement that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) using a &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the shares of our Common Stock through any means described in the section entitled &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; More specific terms of any securities that the Selling Stockholders offer and sell may be provided in a prospectus supplement that describes, among other things, the specific amounts and prices of the Common Stock being offered and the terms of the offering. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A prospectus supplement may also add, update or change information included in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Neither we nor the Selling Stockholders have authorized anyone to provide you with any information other than the information contained or incorporated by reference in this prospectus or any free writing prospectus prepared by or on behalf of us in connection with this offering to which we have referred you. We and the Selling Stockholders take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained or incorporated by reference in this prospectus or any such free writing prospectus provided in connection with this offering is accurate only as of the date thereof, regardless of the time of delivery of such document or of any sale of our Common Stock. Our business, financial condition and results of operations may have changed since those dates. It is important for you to read and consider all the information contained in this prospectus, including the documents incorporated by reference herein or any free writing prospectus prepared by or on behalf of us in connection with this offering, in making your investment decision. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Selling Stockholders are not offering to sell, or seeking offers to buy, shares of our Common Stock in any jurisdictions where offers and sales are not permitted. The distribution of this prospectus and the offering of the Resale Shares in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Resale Shares and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In this prospectus, unless otherwise indicated or the context otherwise requires, the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Catalyst Biosciences, Inc. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_204-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCNR"><!--Anchor--></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus and the documents incorporated by reference herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning our future results of operations and financial position, strategy and plans, and our expectations for future operations. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative version of these words and similar expressions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those described in &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; included elsewhere in this prospectus and in the documents that are incorporated by reference herein. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our beliefs and assumptions only as of the date of this prospectus, or, in the case of any document incorporated by reference herein in this prospectus, as of the date of such document. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. You should read this prospectus and the documents incorporated by reference herein completely and with the understanding that our actual future results may be materially different from what we expect. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These forward-looking statements include, but are not limited to, statements concerning the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to develop a pipeline of product candidates to address unmet needs in the treatment of organ fibrosis and other inflammatory diseases; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the timing, progress and results of clinical trials for Hydronidone from the Company&#8217;s Phase 2a trial and other product candidates that the Company may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available and research and development programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the timing, scope and likelihood of regulatory filings and approvals, including timing of investigational new drug applications and final approval of Hydronidone from the U.S. Food and Drug Administration for the treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;) and liver fibrosis associated with chronic hepatitis B, and any other future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing, scope or likelihood of foreign regulatory filings and approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our expectations regarding the reconsideration of its strategic alternatives in the event the Transactions are not completed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our expectations regarding the future pursuit of product development efforts, including whether it will pursue such efforts, estimates regarding the expenses, future revenue, timing of any future revenue, capital requirements and need for additional financing related to such efforts, the timing of and ability of the Company to pursue such efforts and the Company&#8217;s plans to develop and, if approved, subsequently commercialize any product candidates resulting from such efforts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our expectations regarding its ability to fund its operating expenses and capital expenditure requirements with its cash, cash equivalents and investments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to develop and advance current product candidates and programs into, and successfully complete, clinical studies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our manufacturing, commercialization and marketing capabilities and strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the need to hire additional personnel and our ability to attract and retain such personnel; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_204-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases the Company is targeting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations regarding the approval and use of our product candidates in combination with other drugs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations regarding potential for accelerated approval or other expedited regulatory designation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our competitive position and the success of competing therapies that are or may become available; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">estimates of the number of patients that the Company will enroll in its clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the beneficial characteristics and the potential safety, efficacy and therapeutic effects of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to obtain and maintain regulatory approval of its product candidates and its expectations regarding particular lines of therapy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">plans relating to the further development of our product candidates, including additional indications the Company may pursue; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">existing regulations and regulatory developments in the United States, Europe, and other jurisdictions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations regarding the impact of the COVID-19 pandemic on our business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our intellectual property position, including the scope of protection the Company is able to establish and maintain for intellectual property rights covering Hydronidone, and other product candidates it may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our continued reliance on third parties to conduct additional clinical trials of our product candidates and for the manufacture of its product candidates for clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our relationships with patient advocacy groups, key opinion leaders, regulators, the research community and payors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to obtain and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the pricing and reimbursement of Hydronidone, and other product candidates the Company may develop, if approved; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the rate and degree of market acceptance and clinical utility of Hydronidone, and other product candidates the Company may develop; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our financial performance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the period over which the Company estimates its existing cash and cash equivalents will be sufficient to fund its planned operating expenses and capital expenditure requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">statements regarding the approval and closing of the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing of the consummation of the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to solicit a sufficient number of proxies to approve the change of control resulting from the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfaction of conditions to the completion of the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the expected benefits of the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to complete the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations about the continued listing of Common Stock on The Nasdaq Capital Market; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of laws and regulations; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">expectations regarding the period during which the Company will qualify as a smaller reporting company under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_204-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We have filed with the SEC this registration statement under the Securities Act of 1933, as amended (the&#160;&#8220;Securities Act&#8221;) covering the Common Stock to be offered and sold by this prospectus and any applicable prospectus supplement. This prospectus does not contain all of the information included in the registration statement, some of which is contained in exhibits to the registration statement. In addition, we are subject to the information and periodic and current reporting requirements of the Exchange Act, and in accordance therewith, we file periodic and current reports, proxy statements and other information with the SEC. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You may access our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, proxy statements on Schedule 14A and amendments or supplements to those reports and statements, filed with the SEC, free of charge at our website at <font style="font-style: italic;">www.catalystbiosciences.com </font>or by means of the SEC&#8217;s website at <font style="font-style: italic;">www.sec.gov</font>. The information found on, or that can be accessed from or that is hyperlinked to, our website or the SEC&#8217;s website is not part of this prospectus and you should not rely on that information when making a decision to invest in our Common Stock. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any statement made in this prospectus and any prospectus supplement, periodic and current reports, proxy statements and other information filed or furnished with the SEC concerning the contents of any contract, agreement or other document is only a summary of the actual contract, agreement or other document. If we have filed any contract, document, agreement or other document as an exhibit to such filing or furnishing, you should read the exhibit for a more complete understanding of the document or matter involved. Each statement regarding a contract, agreement or other document is qualified in its entirety by reference to the actual document. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Upon written or oral request, we will provide without charge to each person to whom a copy of the prospectus is delivered a copy of the documents incorporated by reference herein (other than exhibits to such documents unless such exhibits are specifically incorporated by reference herein). You may request a copy of these filings, at no cost, by writing or calling us at the contact information set forth below. We have authorized no one to provide you with any information that differs from that contained in this prospectus. Accordingly, we take no responsibility for any other information that others may give you. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Investor Relations<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">611 Gateway Blvd, Suite 120<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">South San Francisco, CA 94080<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(650) 871-0761 </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_205-info_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIIB"><!--Anchor--></a>INFORMATION INCORPORATED BY REFERENCE </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference herein is considered to be part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below (except the information contained in such documents to the extent &#8220;furnished&#8221; and not &#8220;filed&#8221;) and any future filings we make with the SEC under Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (except the information contained in such documents to the extent &#8220;furnished&#8221; and not &#8220;filed&#8221;): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2022 filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000156459023004830/cbio-10k_20221231.htm">March&#160;30, 2023</a> (and any portions of our Definitive Proxy Statement on Schedule 14A filed on <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123035323/ny20006478x10_defm14a.htm">July&#160;20, 2023</a> that are incorporated by reference into our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Quarterly Report on Form&#160;10-Q for the fiscal quarter ended March&#160;31, 2023 filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000156459023007276/cbio-10q_20230331.htm">May&#160;15, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Current Reports on Form&#160;8-K as filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036123002126/brhc10046770_8k.htm">January&#160;19, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036123009748/brhc10049211_8k.htm">March&#160;2, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036123014819/brhc10050607_8k.htm">March&#160;30, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036123017337/ny20006478x2_8k.htm">April&#160;7, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036123023200/brhc20052574_8k.htm">May&#160;5, 2023</a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036123030517/brhc20054638_8k.htm">June&#160;20, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Definitive Proxy Statement on Schedule 14A filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123035323/ny20006478x10_defm14a.htm">July&#160;20, 2023</a>; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Description of Catalyst Capital Stock section contained in our Definitive Proxy Statement on Schedule&#160;14A filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123035323/ny20006478x10_defm14a.htm">July&#160;20, 2023</a>, including any amendment or report filed for the purpose of updating such description. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We will provide without charge upon written or oral request a copy of any or all of the documents that are incorporated by reference herein into this prospectus, other than exhibits which are specifically incorporated by reference herein into such documents. Requests should be directed to our Investor Relations department at Catalyst Biosciences, Inc., 611 Gateway Blvd, Suite 120, South San Francisco, CA 94080. Our telephone number is (650)&#160;871-0761. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any statement contained in a document incorporated or deemed to be incorporated by reference herein into this prospectus shall be deemed to be modified or superseded for the purposes of this prospectus to the extent that a statement contained in this prospectus (or in any document incorporated by reference herein therein) or in any other subsequently filed document that is or is deemed to be incorporated by reference herein into this prospectus modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20009756x1_s3_206-sum_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPSY"><!--Anchor--></a>PROSPECTUS SUMMARY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You should read the following summary together with the entire prospectus and the documents incorporated by reference herein, including our consolidated financial statements and related notes as well as any free writing prospectus prepared by us or on our behalf. You should carefully consider, among other things, the matters discussed in the sections entitled &#8220;Risk Factors&#8221; included in or incorporated by reference in this prospectus.<font style="font-style: normal;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Our Company </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are a biopharmaceutical company focused on the development and commercialization of Hydronidone for the treatment of NASH in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a broad spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetics (&#8220;PK&#8221;), safety and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We anticipate filing an investigational new drug application for the treatment of NASH in the United States in late 2023. NASH is a severe form of nonalcoholic fatty liver disease, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma and death. There are currently no approved products for the treatment of NASH. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We plan to initiate the clinical development of Hydronidone in NASH fibrosis in a randomized, double-blind, placebo-controlled, parallel group, Phase 2a, Proof-of-Concept (&#8220;PoC&#8221;) clinical study evaluating the safety, tolerability, PK, and Pharmacodynamics (&#8220;PD&#8221;) of Hydronidone capsules administered daily at an oral dose of 360&#160;mg (given as 120 mg thrice daily) for 24 weeks to adult subjects with advanced liver fibrosis associated with noncirrhotic NASH. The main goal of the proposed Phase 2a study is to obtain early PoC for Hydronidone in subjects with NASH fibrosis as a basis of expansion into a more comprehensive Phase 2/3 clinical program, provided that the drug is successful. The study will include a small sample size (total of 60 evaluable subjects) who will receive in a 2:1 ratio Hydronidone or Placebo. The study will evaluate changes from baseline in a set of noninvasive biochemical and imaging biomarkers relevant to assessment of NASH fibrosis in the context of drug exposure, as well as the mechanism of anti-fibrotic action of Hydronidone. The study will employ PK blood sampling and assessment of the initial population PK and PK/PD relationship to inform Hydronidone treatment in future clinical studies in NASH fibrosis. In addition, this trial will include a disease-specific patient-reported outcomes, a validated composite Chronic Liver Disease Questionnaire &#8211; NASH, to collect patient-reported data about the impact of Hydronidone treatment on quality of life of subjects with advanced NASH fibrosis. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Prior to our acquisition from GNI Group Ltd., a company incorporated under the laws of Japan with limited liability and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, of all of the assets and intellectual property rights primarily related to the proprietary Hydronidone compound, other than such assets and intellectual property rights located in the PRC, we were engaged in the research and development of product candidates from our protease engineering platform. In February&#160;2022, we engaged Perella Weinberg Partners as a financial advisor to assist our company in exploring strategic alternatives to monetize our assets. In&#160;March&#160;2022, we ceased research and development activities and in May&#160;2022, we entered into an asset purchase agreement with Vertex Pharmaceuticals Inc., pursuant to which Vertex Pharmaceuticals Inc. (&#8220;Vertex&#8221;) purchased our complement portfolio, including CB 2782-PEG and CB 4332, as well as our complement-related intellectual property, including the ProTUNE&#8482; and ImmunoTUNE&#8482; platforms, for $60.0&#160;million in cash consideration (the &#8220;Vertex Transaction&#8221;). $55.0&#160;million was received upfront in May 2022 and the remaining $5.0&#160;million was received in May 2023 upon satisfaction of certain post-closing indemnification obligations. The hold-back amount was initially recorded within accounts and other receivables on the condensed consolidated balance sheet. In June&#160;2023, we distributed $3.5&#160;million, which reflected, in consideration with the Vertex Transaction, the hold-back amount received from Vertex less expenses and a reserve for potential tax liabilities to holders of the contingent value right issued to our stockholders of record on January&#160;5, 2023 (the &#8220;CVR Holders&#8221;). On February&#160;27, 2023, we signed an asset purchase agreement with GC Biopharma (&#8220;GCBP&#8221;) pursuant to which GCBP acquired our legacy rare bleeding disorders programs, including marzeptacog alpha activated, dalcinonacog alpha and CB-2679d-GT, for a total of $6&#160;million; $1&#160;million payable on signing and $5&#160;million payable on February&#160;28, 2025, subject to satisfaction of post-closing indemnification obligations. In March&#160;2023, we distributed net proceeds of approximately $0.2&#160;million to the CVR Holders. Once received, any additional net proceeds from the transaction will be distributed to the CVR Holders. We&#160;are also pursuing certain legal claims against a third party related to payments under a 2016 asset purchase agreement, and any net recoveries related to these claims will be distributed to the CVR Holders. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20009756x1_s3_206-sum_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We had a net loss of $8.2&#160;million for the year ended December&#160;31, 2022 and net income of $0.3&#160;million for the three months ended March&#160;31, 2023, and an accumulated deficit of $410.9&#160;million as of December&#160;31, 2022 and $410.7&#160;million as of March&#160;31, 2023. As of December&#160;31, 2022, we had $21.7&#160;million of cash and cash equivalents. As of March&#160;31, 2023, we had $8.1&#160;million of cash and cash equivalents. Substantially all our operating losses were incurred in its research and development programs and in our general and administrative operations. We believe that our stockholders who are entitled to vote on the conversion proposal at the Special Meeting will vote to approve the proposal. However, as the vote of our stockholders is outside of our control, there is substantial doubt about our ability to continue as a going concern within one year from the filing of this registration statement. For a description of our business, financial condition, results of operations and other important information regarding us and our business, we refer you to our filings with the SEC, incorporated by reference in this prospectus. For instructions on how to find copies of these documents, see &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>.&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Corporate Information </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We were incorporated in Delaware in 1997 as a wholly-owned subsidiary of R.J. Reynolds Tobacco Company. In August&#160;2000, we became an independent company when we issued and sold stock to venture capital investors. On&#160;August&#160;20, 2015, pursuant to the merger agreement between Targacept, Inc. and Catalyst Biosciences, Inc. (&#8220;Private Catalyst&#8221;), we acquired Private Catalyst and on August&#160;20, 2015, we changed our name from Targacept, Inc. to Catalyst Biosciences, Inc. Our principal executive offices are located at 611 Gateway Blvd, Suite 120, South&#160;San&#160;Francisco, CA 94080, and our telephone number is (650) 871-0761. Our website address is <font style="font-style: italic;">https://www.catalystbiosciences.com</font>. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We own various U.S. federal trademark registrations and applications and unregistered trademarks, including our corporate logo. This prospectus contains additional trade names, trademarks and service marks of ours and of other companies. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20009756x1_s3_206-sum_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTO"><!--Anchor--></a>THE OFFERING </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Common Stock offered by the Selling Stockholders<font style="font-weight: normal; padding-left: 3.96pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">1,240,442,745 shares of Common Stock. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of proceeds<font style="font-weight: normal; padding-left: 1.38pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">We will not receive any proceeds from the sale of our Common Stock by the Selling Stockholders pursuant to this prospectus. See &#8220;<font style="font-style: italic;">Use of Proceeds</font>&#8221; and &#8220;<font style="font-style: italic;">Selling&#160;Stockholders</font>.&#8221; </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Plan of distribution<font style="font-weight: normal; padding-left: 2.52pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">The Selling Stockholders may sell all or a portion of the Resale Shares owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. Registration of the Resale Shares covered by this prospectus does not mean, however, that such shares necessarily will be offered or sold. See &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk factors<font style="font-weight: normal; padding-left: 5.3pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">Investing in our Common Stock involves a high degree of risk. See &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; and other information included or incorporated into this prospectus for a discussion of the factors you should carefully consider before deciding to invest in our Common Stock. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Nasdaq Capital Market Symbol<font style="font-weight: normal; padding-left: 1.21pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">Our Common Stock is currently listed on Nasdaq under the symbol &#8220;CBIO.&#8221; We have applied to continue the listing of our Common Stock on Nasdaq under the symbol &#8220;GYRE&#8221; upon the completion of the Transactions.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_207-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRFS"><!--Anchor--></a>RISK FACTORS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Investing in our Common Stock involves a high degree of risk. You should consider carefully the risks and uncertainties described in the section entitled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; contained in our most recent Annual Report on Form&#160;10-K and our Definitive Proxy Statement on Schedule 14A filed with the SEC on July&#160;20, 2023, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with all of the other information contained in this prospectus or any document incorporated by reference herein and any free writing prospectus that we may authorize for use in connection with this offering. The risks described in this prospectus or any document incorporated by reference herein are not the only risks facing us, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past&#160;financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be adversely affected, which could cause the trading price of our Common Stock to decline, resulting in a loss of all or part of your investment. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_208-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUOP"><!--Anchor--></a>USE OF PROCEEDS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Subject to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_208-use_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSSS"><!--Anchor--></a>SELLING STOCKHOLDERS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus relates to the resale by the Selling Stockholders from time to time of up to 1,240,442,745 shares of our Common Stock, including shares of our Common Stock that are issuable to the Selling Stockholders pursuant to the Business Combination Agreement and shares of our Common Stock that are issuable to the Selling Stockholders upon conversion of the Convertible Preferred Stock. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. When we refer to the &#8220;Selling Stockholders&#8221; in this prospectus, we mean the persons listed in the table below, and the pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the Selling Stockholders&#8217; interest in the Resale Shares other than through a public sale. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Certain Information Concerning the Selling Stockholders </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The table below presents information regarding the Selling Stockholders and the shares of our Common Stock that they may sell or otherwise dispose of from time to time under this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In accordance with the F351 Agreement, on December&#160;26, 2022, our board of directors appointed two persons affiliated with GNI USA, Ying Luo, Ph.D. and Mr.&#160;Thomas Eastling, to our board as directors. Dr.&#160;Luo will serve as a Class&#160;I director with a term expiring at our 2025 annual meeting of the stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr.&#160;Eastling will serve as a Class&#160;III director with a term expiring at our 2024 annual meeting of the stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. GNI USA, through entities affiliated with GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;GNI Japan&#8221;), is a wholly-owned subsidiary of GNI Japan. Dr.&#160;Luo is a director, representative executive officer, president and chief executive officer and executive committee member of GNI Japan. Mr.&#160;Eastling is an outside member of GNI Japan and an advisor to the executive committee of GNI Japan. Except as disclosed herein, other Selling Stockholders do not have, and within the past three years have not had, any position, office or other material relationship with us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For the Selling Stockholders collectively listed on the table below, we have calculated the maximum estimated number of Resale Shares that could become saleable by such Selling Stockholders pursuant to this prospectus if such Selling Stockholders were to convert their shares of our Convertible Preferred Stock into shares of our Common Stock at a rate equal to $10,000 per share divided by the $1.00. On an aggregate basis, the total number of the Resale Shares saleable pursuant to this prospectus is 1,240,442,745 shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For purposes of the table below, we have assumed that the Selling Stockholders will not acquire beneficial ownership of any additional securities during the offering. The following table is prepared based on information provided to us by the Selling Stockholders. In addition, we assume that the Selling Stockholders have not sold, transferred or otherwise disposed of, our Common Stock in transactions exempt from the registration requirements of the Securities Act. Any changed or new information given to us by the Selling Stockholders, including regarding the identity of, and the securities held by, each Selling Stockholder, will be set forth in a prospectus supplement or amendments to the registration statement of which this prospectus is a part, if and when necessary. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We have determined beneficial ownership in accordance with the rules of the SEC. Beneficial ownership generally includes voting or investment power over securities. Except in cases where community property laws apply or as indicated in the footnotes to this table, to our knowledge, each Selling Stockholder identified in the table possesses sole voting and investment power over the Resale Shares shown as beneficially owned by the Selling Stockholder. The information is not necessarily indicative of beneficial ownership for any other purpose. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_208-use_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 31.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficial Ownership Prior to the Date of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">this Prospectus</div></td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 28.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficial Ownership Assuming the <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sale of All Shares registered pursuant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to this Prospectus </div></td></tr><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Following <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conversion<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.92%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI USA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 0.66pt;"></font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;">1,083,488,317</div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.94pt; text-align: left;">85.17%</div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.07pt; text-align: left;">0</div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.13%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.92pt; text-align: left;">0% </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ping Lan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 12.5pt;">42,605,648</font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.94pt; text-align: left;"><font style="padding-left: 5pt;">3.35%</font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.07pt; text-align: left;">0</div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.13%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.92pt; text-align: left;">0% </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hui Sun<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 2.87pt;"></font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 12.5pt;">34,084,519</font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.94pt; text-align: left;"><font style="padding-left: 5pt;">2.68%</font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.07pt; text-align: left;">0</div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.13%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.92pt; text-align: left;">0% </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Yueying Zhu<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 3.99pt;"></font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 12.5pt;">44,137,006</font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.94pt; text-align: left;"><font style="padding-left: 5pt;">3.47%</font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.07pt; text-align: left;">0</div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.13%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.92pt; text-align: left;">0% </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arthur Xin-bin Cheng<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 12.5pt;">36,127,255</font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.94pt; text-align: left;"><font style="padding-left: 5pt;">2.84%</font></div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.07pt; text-align: left;">0</div></td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.92%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.13%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.92pt; text-align: left;">0%</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 16pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">One share of Convertible Preferred Stock converts into 10,000 shares of Common Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Based upon 1,272,151,116 shares of Common Stock outstanding assuming the conversion of all shares of Convertible Preferred Stock that a Selling Stockholder beneficially owns into shares of Common Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">GNI USA, through entities affiliated with GNI Japan, is a wholly-owned subsidiary of GNI Japan. By virtue of such relationship, GNI Japan may be deemed to have voting and investment power with respect to the shares held by GNI USA. Ying Luo, Ph.D. is a director, representative executive officer, president and chief executive officer and executive committee member of GNI Japan and may be deemed to share voting and dispositive power over the shares held of record by GNI USA. The business address for GNI USA is 12730 High Bluff Drive, Suite 250, San Diego, California 92130. The address for GNI Japan and Ying Luo, Ph.D. is c/o GNI Group Ltd., Nihonbashi-Honcho YS Bldg. 3rd Floor 2-2-2 Nihonbashi-Honcho, Chuo-ku, 103-0023 Tokyo, Japan. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The business address for Ping Lan is c/o Beijing Continent Pharmaceuticals Co., Ltd, Room 320507-320509, Building 5, Wangjing SOHO Tower, Yard 1, Futong East Street, Chaoyang District, Beijing, PRC. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The business address for Hui Sun is c/o Beijing Continent Pharmaceuticals Co., Ltd, Room 320507-320509, Building 5, Wangjing SOHO Tower, Yard 1, Futong East Street, Chaoyang District, Beijing, PRC. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The business address for Yueying Zhu is c/o Beijing Continent Pharmaceuticals Co., Ltd, Room 320507-320509, Building 5, Wangjing SOHO Tower, Yard 1, Futong East Street, Chaoyang District, Beijing, PRC. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The business address for Arthur Xin-bin Cheng is c/o Beijing Continent Pharmaceuticals Co., Ltd, Room 320507-320509, Building 5, Wangjing SOHO Tower, Yard 1, Futong East Street, Chaoyang District, Beijing, PRC. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_209-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Selling Stockholders may sell all or a portion of the Resale Shares covered by this prospectus from time to time. The Selling Stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made directly or through one or more underwriters, broker-dealers or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts or commissions or agent&#8217;s commissions. The Resale Shares may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling the Resale Shares: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">on the Nasdaq, in the over-the-counter market or on any other national securities exchange on which our securities are listed or traded; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in privately negotiated transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in underwritten offerings; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">in a block trade in which the broker-dealer will attempt to sell the offered shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through purchases by a broker-dealer as principal and resale by the broker-dealer for its account pursuant to this prospectus; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through the writing of options (including put or call options), whether the options are listed on an options exchange or otherwise; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through the distribution of the shares by any Selling Stockholder to its partners, members or stockholders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">in short sales entered into after the effective date of the registration statement of which this prospectus is a part; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by pledge to secured debts and other obligations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through delayed delivery arrangements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exchange distribution in accordance with the rules of the applicable exchange; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through delayed delivery arrangements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to or through underwriters or agents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;at the market&#8221; or through market makers or into an existing market for the securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through trading plans entered into by a Selling Stockholder pursuant to Rule&#160;10b5-1 under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of securities on the basis of parameters described in such trading plans; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a combination of any such methods of sale. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Selling Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule&#160;144 under the Securities Act, as permitted by that rule, or Section&#160;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect such transactions by selling the Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_209-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule&#160;2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule&#160;2121.01. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Selling Stockholders may transfer and donate the Resale Shares in other circumstances in which case the transferees, donees or pledgees will be the selling beneficial owners for purposes of this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of Section&#160;2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the Resale Shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Selling Stockholders may also sell our securities short and deliver the securities to close out their short positions or loan or pledge the securities to broker-dealers that in turn may sell the securities. The shares may be sold directly or through broker-dealers acting as principal or agent or pursuant to a distribution by one or more underwriters on a firm commitment or best-efforts basis. The Selling Stockholders may also enter into hedging transactions with broker-dealers. In connection with such transactions, broker-dealers of other financial institutions may engage in short sales of our securities in the course of hedging the positions they assume with the Selling Stockholders. The Selling Stockholders may also enter into options or other transactions with broker-dealers or other financial institutions, which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each Selling Stockholder has informed the Company that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Resale Shares. Upon the Company being notified in writing by a Selling Stockholder that any material arrangement has been entered into with a broker-dealer for the Resale Shares through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule&#160;424(b) under the Securities Act, disclosing (i) the name of each such Selling Stockholder and of the participating broker-dealer(s), (ii) the number of Resale Shares involved, (iii) the price at which the Resale Shares were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, and (vi) other facts material to the transaction. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Under the securities laws of some U.S. states, shares of our Common Stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states shares of our Common Stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration statement, of which this prospectus is a part. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each Selling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Selling Stockholders will pay all of the expenses incurred in connection with the registration of the Resale Shares, including, without limitation, SEC filing fees and expenses of compliance with state securities or &#8220;blue sky&#8221; laws, all underwriting discounts and selling commissions, if any, and any legal or other expenses incurred by us or them in connection with the registration and offer and sale of the Resale Shares. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_210-dividend_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDPY"><!--Anchor--></a>DIVIDEND POLICY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September&#160;20, 2022, we paid a special, one-time cash dividend of approximately $45.0&#160;million (or&#160;$1.43&#160;per&#160;share) to our common stockholders of record as of the close of business on September&#160;6, 2022. On January&#160;12, 2023, we paid a special, one-time cash dividend of approximately $7.6 million (or $0.24 per share) to our common stockholders of record as of the close of business on January&#160;5, 2023. In June 2023, we distributed $3.5&#160;million, which reflected, in connection with the Vertex Transaction, the hold-back amount received from Vertex less expenses and a reserve for potential tax liabilities, to the CVR Holders. We currently intend to retain all future earnings, if any, for use in our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors our board of directors may deem relevant. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_210-dividend_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLMS"><!--Anchor--></a>LEGAL MATTERS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The validity of the issuance of the Resale Shares offered by this prospectus has been passed upon for us by Orrick Herrington &amp; Sutcliffe LLP, New York, New York. Certain legal matters in connection with the Resale Shares offered hereby will be passed on for any agents, dealers or underwriters by counsel that will be named in the applicable prospectus supplement. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_210-dividend_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tEX"><!--Anchor--></a>EXPERTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The consolidated balance sheets of Catalyst Biosciences, Inc. and Subsidiary as of December&#160;31, 2022 and 2021, and the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cashflows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report, which is incorporated herein by reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company&#8217;s ability to continue as a going concern. Such financial statements have been incorporated herein by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The consolidated financial statements of Beijing Continent Pharmaceuticals Co., Ltd. at December&#160;31, 2022 and 2021, and for each of the years then ended, which are incorporated by reference in this Prospectus and Registration Statement, have been audited by Ernst &amp; Young Hua Ming LLP, independent registered public accounting firm, as set forth in their report thereon, including therein, and are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20009756x1_s3_300-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 126.75pt; text-align: center;"><img style="height: 121px; width: 383px;" src="logo_catalystbiox1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 68.5pt; text-align: center;">1,240,442,745 Shares<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">COMMON STOCK<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offered by the Selling Stockholders </div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">PROSPECTUS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; text-align: center;"><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 6pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 248.5pt; text-align: center;">The date of this prospectus &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2023</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_301-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPART2"><!--Anchor--></a>PART II <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INFORMATION NOT REQUIRED IN PROSPECTUS</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Other Expenses of Issuance and Distributions. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table sets forth the expenses to be borne by Catalyst Biosciences, Inc. in connection with the offerings described in this Registration Statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Registration fee&#8201;&#8211;&#8201;Securities and Exchange Commission<font style="padding-left: 0.24pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$57,152.93 </div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Printing and engraving expenses<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">* </font></div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">* </font></div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">* </font></div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfer agent fees and expenses<font style="padding-left: 3.38pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">* </font></div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 45pt;"></font></div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt; border-bottom: 3pt double #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">*</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 10pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Directors and Officers. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section&#160;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section&#160;145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As permitted by the Delaware General Corporation Law, our restated certificate of incorporation and amended and restated bylaws contain provisions relating to the limitation of liability and indemnification of directors and officers. The restated certificate of incorporation provides that our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for any breach of the director&#8217;s duty of loyalty to us or our stockholders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">under Section&#160;174 of the Delaware General Corporation Law; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for any transaction from which the director derived an improper personal benefit. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our restated certificate of incorporation also provides that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law as so amended. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law, as it now exists or may in the future be amended (but, in the case of any amendment, only to the extent such amendment permits broader indemnification rights than such law permitted us prior to such amendment), against all expenses reasonably incurred in connection with their service for or on our behalf. Our amended and restated bylaws provide that we shall advance the expenses incurred by a director or officer in advance of the final disposition of an action or proceeding; provided, however, that if the Delaware General Corporation Law so requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including without limitation, service to an employee benefit plan) will be made only upon delivery to us of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it is ultimately determined that such indemnitee is not entitled to be indemnified by us under our amended and restated bylaws or otherwise. Our amended and restated bylaws permit us to secure insurance on behalf of any director, officer, employee, or agent or individual serving at the request of us as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_301-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">or arising out of such person&#8217;s status as such, whether or not we would have the power or the obligation to indemnify such person against such liability under the provisions of our amended and restated bylaws. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We have entered into indemnification agreements with each of our directors and with each executive officer. Pursuant to the indemnification agreements, we have agreed to indemnify and hold harmless these directors and officers to the fullest extent permitted by the Delaware General Corporation Law. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of our company. The agreements also provide for the advancement of expenses to the directors and officers subject to specified conditions. There are certain exceptions to our obligation to indemnify the directors and officers, including any intentional malfeasance or act where the director or officer did not in good faith believe he or she was acting in our best interests, with respect to &#8220;short-swing&#8221; profit claims under Section&#160;16(b) of the Exchange Act and, with certain exceptions, with respect to proceedings that he or she initiates. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 6.2%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.03%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 42.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incorporated by reference herein</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 6.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exhibit&#160;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 41.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Form</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">File No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 20.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Filing Date</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Filed <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Herewith </div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex2-1.htm">2.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Asset Purchase Agreement, dated December&#160;26, 2022, by and among Catalyst Biosciences, Inc., GNI Group Ltd., and GNI Hong Kong Limited</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;27, 2022</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-2.htm">2.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement and Amendment to Asset Purchase Agreement, dated as of March&#160;29, 2023, by and among Catalyst, GNI Group and GNI HK.</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;30, 2023</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex2-2.htm">2.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Business Combination Agreement, dated December&#160;26, 2022, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the individuals listed on Annex&#160;A thereto and Continent Pharmaceuticals Inc.</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;27, 2022</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-1.htm">2.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment to Business Combination Agreement, dated as of March&#160;29, 2023, by and among Catalyst, GNI USA, GNI Group, GNI HK, Shanghai Genomics, the Minority Holders and CPI.</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;30, 2023</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20009756x1_ex2-5.htm">2.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contingent Value Rights Agreement, dated as of December&#160;26, 2022, between Catalyst and American Stock Transfer &amp; Trust Company, LLC</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">X</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-3.htm">2.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment to Contingent Value Rights Agreement, dated as of March&#160;29, 2023, executed by Catalyst.</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;30, 2023</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312506103288/dex41.htm">3.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fourth Amended and Restated Certificate of Incorporation of the Registrant</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">S-8</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">333-133881</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;8, 2006</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312515297752/d24322dex31.htm">3.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">August&#160;20, 2015</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312517037156/d326649dex31.htm">3.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">February&#160;10, 2017</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_301-part2_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 6.2%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.03%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 42.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incorporated by reference herein</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 6.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exhibit&#160;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 41.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Form</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">File No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 20.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Filing Date</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Filed <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Herewith </div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex3-1.htm">3.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation of Series&#160;X Convertible Preferred Stock</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;27, 2022</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123030517/brhc20054638_ex3-1.htm">3.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation of Series&#160;Y Preferred Stock</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;20, 2023</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex3-2.htm">3.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Bylaws of the Registrant</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;27, 2022</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20009756x1_ex5-1.htm">5.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion and Consent of Orrick Herrington &amp; Sutcliffe LLP</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">X </div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20009756x1_ex23-1.htm">23.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of EisnerAmper LLP</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">X </div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20009756x1_ex23-2.htm">23.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Ernst &amp; Young Hua Ming LLP</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">X </div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20009756x1_ex5-1.htm">23.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Orrick Herrington &amp; Sutcliffe LLP (contained in Exhibit&#160;5.1)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">X </div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOA">24.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Power of Attorney (contained in the signature page hereto)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">X </div></td></tr><tr><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20009756x1_ex107.htm">107</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filing Fee Table</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.2%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">X</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act of 1934, as amended, that might be incurred by any director or officer in his capacity as such. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; filed as an exhibit in the effective registration statement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; <font style="font-style: italic;">provided, however,</font> that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference herein in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the registration statement. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide </font>offering thereof. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_301-part2_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the registrant is relying on Rule&#160;430B, </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(A)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(B)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section&#160;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <font style="font-style: italic;">Provided, however,</font> that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference herein into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If the registrant is subject to Rule&#160;430C, each prospectus filed pursuant to Rule&#160;424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. <font style="font-style: italic;">Provided, however, </font>that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference herein into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference herein in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_301-part2_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes that: in a registration statement permitted by Rule&#160;430A, </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the Registrant pursuant to Rule&#160;424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009756x1_s3_302-sig_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSI"><!--Anchor--></a>SIGNATURES </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, Catalyst Biosciences, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&#160;S-3 and has duly caused this Registration Statement on Form&#160;S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on the 24th day of July, 2023. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="7" style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc. </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Nassim Usman, Ph.D.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;"><a name="tPOA"><!--Anchor--></a>Power of Attorney </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each person whose signature appears below hereby severally constitutes and appoints Nassim Usman and Seline Miller, and each of them singly, with the power to act without the other, as attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form&#160;S-3, and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule&#160;462 promulgated under the Securities Act of 1933, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting to said attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form&#160;S-3 has been signed below by the following persons in the capacities and on the dates indicated. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 25.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Signature</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Nassim Usman, Ph.D.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer, Director <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">(Principal Executive Officer)</font></div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July 24, 2023 </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Seline Miller</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Chief Financial Officer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">(Interim Principal Financial Officer and </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">Principal Accounting Officer)</font></div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July 24, 2023 </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seline Miller</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo, Ph.D.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the Board</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July 24, 2023 </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Augustine Lawlor</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July 24, 2023 </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Augustine Lawlor</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Thomas Eastling</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July 24, 2023 </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Eastling</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Andrea Hunt</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July 24, 2023 </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Andrea Hunt</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-6<br></div></div></div>
<!--End Page 27-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.5
<SEQUENCE>2
<FILENAME>ny20009756x1_ex2-5.htm
<DESCRIPTION>EXHIBIT 2.5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">

  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 2.5</font><br>
       </div>
    <div style="text-align: right;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div><br>

      <div>Certain information identified by bracketed asterisks ([***]) has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.</div>
      <div><br>
         </div>
      <div style="text-align: center; font-weight: bold;">CONTINGENT VALUE RIGHTS AGREEMENT</div>
      <div><br>
         </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">THIS CONTINGENT VALUE RIGHTS AGREEMENT</font><font style="font-size: 10pt;"> (this &#8220;<u>Agreement</u>&#8221;), dated as of December 26,
          2022 (the &#8220;<u>Effective Date</u>&#8221;), is entered into by and between Catalyst Biosciences, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and American Stock Transfer &amp; Trust Company, LLC, a New York limited liability company, as initial
          Rights Agent (as defined herein).</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">RECITALS</div>
      <div><br>
         </div>
      <div style="text-align: justify; text-indent: 36pt;">WHEREAS, on December 22, 2022, the Board of Directors of the Company authorized and declared a dividend distribution of one CVR right for each share of Company common stock
        outstanding at the close of business on the Record Date (defined below);</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">WHEREAS, the Company intends the distribution of the rights underlying the CVRs to be complete and irrevocable and hereby assigns to the Holders the right to receive the Payment
        Amounts (as defined below); and</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">WHEREAS, the parties have done all things necessary to make the CVR, when issued hereunder, the valid obligation of the Company and to make this Agreement a valid and binding
        agreement of the Company, in accordance with its terms.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 31.5pt; margin-left: 4.5pt;">NOW, THEREFORE, in consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for the
        proportionate benefit of all Holders (as defined below), as follows:</div>
      <div>&#160;</div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">ARTICLE 1</font><br>
         <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">DEFINITIONS</font></div>
      <div style="text-align: center;">&#160;</div>
      <div style="text-indent: 36pt;">Section 1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Definitions.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Capitalized terms used but not otherwise defined herein have the meanings ascribed to thereto in the Business Combination Agreement. The following terms have the meanings ascribed
        to them as follows:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Affiliate</u>&#8221; shall have the meaning given to such term in Rule 145 under the Securities Act.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Asset Purchase Agreement</u>&#8221; means the Asset Purchase Agreement, dated as of May 19, 2022, by and between the Company and Vertex Pharmaceuticals Incorporated.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Assignee</u>&#8221; has the meaning set forth in Section 6.6.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Business Combination Agreement</u>&#8221; means that certain Business Combination Agreement, dated as of December 26, 2022, by and among the Company, GNI Group Ltd., GNI Hong Kong
        Limited, GNI USA, Inc., Shanghai Genomics, Inc., Continent Pharmaceuticals Inc., and the Minority Holders (as defined in the Business Combination Agreement).</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Business Day</u>&#8221; means any day other than a day on which banks in the state of New York are authorized or obligated to be closed.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Claim</u>&#8221; means any pending, threatened, or potential claim, suit, proceeding, investigation arbitration, or other legal right that the Company has or may have during the Term
        against any third party related to the Company&#8217;s business on or before the Effective Time.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Code</u>&#8221; has the meaning set forth in Section 2.3(d).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>CVR</u>&#8221; means a contingent contractual right of Holders to receive the Payment Amounts pursuant to this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>CVR Register</u>&#8221; has the meaning set forth in Section 2.2(b).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Disposition</u>&#8221; means (i)&#160;the sale, license, transfer or other disposition to a third party of any rights or assets comprising the Legacy Assets, including any sale or
        disposition of equity securities in any Subsidiary established by the Company to hold any right, title or interest in any Legacy Assets, or (ii)&#160;the settlement, court order, arbitration ruling, or other disposition of any Claim resulting in payment
        or the right to receive payment, in each case, during the Disposition Period.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Disposition Agreement</u>&#8221; means a definitive written agreement providing for (i)&#160;a Disposition of any portion of the Legacy Assets during the Disposition Period or (ii)&#160;the
        settlement of any Claim.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Disposition Period</u>&#8221; means the two-year period following the Record Date; <font style="font-style: italic;"><u>provided</u></font>,&#160;<font style="font-style: italic;"><u>however</u></font>,
        such period will be automatically extended for any Claim for an additional one-year period to the extent any Claim is appealed during the initial two-year term.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Excluded Taxes</u>&#8221; has the meaning set forth in Section 3.2(g).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Holder</u>&#8221; means, at the relevant time, a Person in whose name CVRs are registered in the CVR Register.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Incurred Fees</u>&#8221; has the meaning set forth in Section 4.4(c).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Interim Operating Amount</u>&#8221; has the meaning set forth in the Business Combination Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Law</u>&#8221; means any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code,
        edict, decree, rule, regulation, ruling, or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any governmental authority (including under the authority of Nasdaq or the
        Financial Industry Regulatory Authority).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Legacy Assets</u>&#8221; means [***].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Loss</u>&#8221; has the meaning set forth in Section 3.2(g).</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Majority of Holders</u>&#8221; means, at any time, the registered Holder or Holders of more than 50% of the total number of CVRs registered at such time, as set forth on the CVR
        Register, except that with respect to the use of the term <font style="font-style: italic;">Majority of Holders</font> in Section 6.7, the term shall mean the registered Holder or Holders of more than 25% of the total number of CVRs registered at
        such time, as set forth on the CVR Register.</div>
      <br>

      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Notice</u>&#8221; has the meaning set forth in Section 6.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Officer&#8217;s Certificate</u>&#8221; means a certificate signed by the chief executive officer and the principal financial and accounting officer of the Company, in their respective
        official capacities.</div>
      <div> <br>
         </div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Payment Amount</u>&#8221; means, with respect to any Payment Triggering Event: (i)&#160;100% of the amount actually received (net of out-of-pocket and documented transaction expenses and
        potential indemnification obligations) by the Company pursuant to any Disposition Agreement; (ii)&#160;100% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses and unpaid severance or change of
        control payment obligations) retained by the Company in excess of $1,000,000 as of the Closing of the Closing Date (as defined in the Business Combination Agreement); (iii)&#160;100% of the amount actually received (net of indemnity claims, if any) by
        the Company pursuant to the Asset Purchase Agreement; and (iv)&#160;100% of the excess, if any, by which the Interim Operating Amount exceeds the Incurred Fees, in each case net of: (a)&#160;any Tax incurred by the Company or such Affiliate(s) as a result of
        the receipt of such payment and (b)&#160;the reasonable costs, out-of-pocket fees, expenses or charges incurred, directly or indirectly, by the Rights Agent, the Company or the Company&#8217;s Affiliates (but subject to Section 4.4), or for which the Rights
        Agent, the Company or the Company&#8217;s Affiliates (subject to Section 4.4) are responsible, in connection with such Payment Triggering Event (in each case to the extent such costs, fees, expenses or charges have not been previously accounted for in
        the calculation of a prior Payment Amount).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Payment Triggering Event</u>&#8221; means the actual receipt by the Rights Agent or the Company following the Record Date of: (i) any cash payment pursuant to a Disposition
        Agreement, (ii) Net Cash (as defined in the Business Combination Agreement) over $1,000,000 immediately following the Closing Date, (iii)&#160; any cash received by the Company under the Asset Purchase Agreement (net of indemnity claims, if any), and
        (iv)&#160;the excess, if any, by which the Interim Operating Amount exceeds the Incurred Fees under Section 4.4(c).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Permitted Transfer</u>&#8221; means a transfer of CVRs (i)&#160;upon death of a Holder by will or intestacy, (ii)&#160;pursuant to a court order, (iii)&#160;by operation of law (including by
        consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity, (iv) in the case of CVRs held in book-entry or other
        similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, or (v) as provided in Section 2.5.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Person</u>&#8221; means any individual, corporation, partnership, joint venture, estate, trust, company, firm, limited liability company, firm, society or other enterprise,
        association, organization, or any other entity not specifically listed herein, including any governmental authority.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Pro Rata Share</u>&#8221; means, with respect to any Holder, the quotient obtained by dividing (i) the aggregate number of CVRs held by such Holder by (ii) the aggregate number of
        outstanding CVRs held by all Holders, in each case, as reflected in the CVR Register.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Record Date</u>&#8221; means January 5, 2023.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Rights Agent</u>&#8221; means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent shall have been appointed pursuant to <u>ARTICLE 3</u>
        of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Special Committee</u>&#8221; means an oversight committee initially comprised of the following individuals: Nassim Usman, Ph.D., Augustine Lawlor and Andrea Hunt, and such additional
        members as may be added by the Special Committee, from time to time.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">An entity shall be deemed to be a &#8220;<u>Subsidiary</u>&#8221; of a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a) an amount of voting
        securities or other interests in such entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body, or (b) at least 50% of the outstanding equity, voting,
        beneficial or financial interests in such entity.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">&#8220;<u>Tax</u>&#8221; means any federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax,
        estimated tax, unemployment tax, national health insurance tax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, customs duty, alternative or add-on minimum or other
        tax of any kind whatsoever, and including any fine, penalty, addition to tax or interest imposed by a governmental authority with respect thereto.</div>
      <div>&#160;</div>
      <br>

      <div style="text-align: center;"><font style="font-weight: bold;">ARTICLE 2</font> </div>
      <div style="text-align: center;"><font style="font-weight: bold;">CONTINGENT VALUE RIGHTS</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 2.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Holders of CVRs; Appointment of Rights Agent; Assignment of Rights.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The initial Holders shall be the holders of shares of the Company&#8217;s common stock as of the close of business on the Record Date.
          Effective five Business Days following the Record Date, each initial Holder shall be issued and distributed in the form of a dividend one CVR for each share of Company common stock held of record by such Holder as of the close of business on the
          Record Date. Notwithstanding anything to the contrary in this Agreement, in no event shall any CVRs be issued pursuant to this Agreement prior to five Business Days following the Record Date.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company hereby appoints the Rights Agent to act as rights agent for the Company in accordance with the express terms and conditions
          set forth in this Agreement, and the Rights Agent hereby accepts such appointment.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 2.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">No Certificate; Registration; Registration of Transfer; Change of Address;
            CVR Distribution.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Holders&#8217; rights and obligations in respect of CVRs derive solely from this Agreement; CVRs will not be evidenced by a certificate or
          other instrument.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent will create and maintain a register (the &#8220;<u>CVR Register</u>&#8221;) for the purposes of (i) identifying the Holders of
          CVRs, (ii) determining the Holders&#8217; entitlement to CVRs and (iii) registering the CVRs and Permitted Transfers thereof. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from
          Company. Except for the obligations to the Rights Agent set forth herein, neither the Company nor its Subsidiaries will have any responsibility or liability whatsoever to any Person other than the Holders.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the restrictions on transferability set forth in Section 2.6, every request made to transfer CVRs must be in writing and
          accompanied by a written instrument of transfer reasonably acceptable to the Rights Agent, together with the signature guarantee of a guarantor institution which is a participant in a signature guarantee program approved by the Securities
          Transfer Association (a &#8220;signature guarantee&#8221;) and other requested documentation in a form reasonably satisfactory to the Rights Agent, duly executed and properly completed, as applicable, by the Holder or Holders thereof, or by the duly
          appointed legal representative, personal representative or survivor of such Holder or Holders, setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent will, subject to
          its reasonable determination in accordance with its own internal procedures, that the transfer instrument is in proper form and otherwise complies on its face with the other terms and conditions of this Agreement (including the provisions in
          Section 2.6), register the transfer of the applicable CVRs in the CVR Register. All transfers of CVRs registered in the CVR Register will be the valid obligations of the Company, evidencing the same right, and entitling the transferee to the same
          benefits and rights under this Agreement, as those held by the transferor. The Company and the Rights Agent may each require evidence of payment of a sum sufficient to cover any stamp or other transfer tax or governmental charge that is imposed
          in connection with (and would not have been imposed but for) any such registration of transfer (or evidence that such Taxes and charges are not applicable). No transfer of CVRs shall be valid until registered in the CVR Register and unless such
          transfer would not violate the Securities Act. Any putative transfer not duly registered in the CVR Register or in violation of the Securities Act shall be void.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. Such written
          request must be duly executed by such Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the CVR Register.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will provide written instructions to the Rights Agent for the distribution of CVRs to the Holders as of the Record Date. The
          Company shall inform Rights Agent of the Record Date at least five business days prior thereto. Subject to the terms and conditions of this Agreement and the Company&#8217;s confirmation of the Record Date, the Rights Agent hereunder shall make the CVR
          distribution, less any applicable withholding taxes imposed pursuant to Section 2.3(d), to each Holder as of the Record Date, five Business Days following the Record Date, by the mailing of a statement of holding reflecting CVRs.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Payment Procedures.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a Payment Triggering Event occurs at any time prior to the termination of this Agreement then, within 10 calendar days after the
          occurrence of such Payment Triggering Event, the Company will deliver to the Rights Agent (i) an Officer&#8217;s Certificate certifying the date of the Payment Triggering Event, the amount of the payment and that the Holders are entitled to receive the
          applicable Payment Amount in respect thereof (the &#8220;<u>Payment Triggering Event Notice</u>&#8221;), and (ii) an amount in cash equal to the applicable Payment Amount (for further distribution to the Holders in accordance with the terms hereof) by wire
          transfer of immediately available funds to an account designated by the Rights Agent.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon receipt of either the Payment Amount or the wire transfer referred to in Section 2.3(a), the Rights Agent will promptly (and in any
          event within 10 Business Days) pay, by check mailed, first-class postage prepaid, to the address of each Holder set forth in the CVR Register at such time or by other method of delivery as specified by the applicable Holder in writing to the
          Rights Agent, an amount in cash equal to such Holder&#8217;s Pro Rata Share of the applicable Payment Amount.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to any Payment Amount that is paid to the Company or an Affiliate of the Company, the Company shall have no further
          liability in respect of such Payment Amount upon delivery of the relevant funds to the Rights Agent in accordance with Section&#160;2.3(a).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and the Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, from any amounts
          required to be paid or distributed under this Agreement (including any Payment Amount payable pursuant to this Agreement), such amounts as it is required to deduct and withhold with respect to the making of such payment or distribution (including
          in respect of the distribution of CVRs) under any provision of applicable Law relating to Taxes. To the extent that amounts are so deducted and withheld, such deducted and withheld amounts will be treated for all purposes of this Agreement as
          having been paid or distributed to the Holder in respect of which such deduction and withholding was made. Prior to making any such Tax deductions or withholdings or causing any such Tax deductions or withholdings to be made with respect to any
          Holder, the Rights Agent will, to the extent reasonably practicable, provide notice to the Holder of such potential Tax deduction or withholding and a reasonable opportunity for the Holder to provide any necessary Tax forms in order to avoid or
          reduce such withholding amounts; <font style="font-style: italic;"><u>provided</u></font>, that the time period for payment of a Payment Amount by the Rights Agent set forth in Section 2.3(b) will be extended by a period equal to any delay
          caused by the Holder providing such forms, <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>further</u></font>, that in no event shall such period be extended for more than ten Business Days, unless
          otherwise requested by the Holder for the purpose of delivering such forms and agreed to by the Rights Agent. The Rights Agent will solicit from each Holder an appropriate Internal Revenue Service Form W-8 or Internal Revenue Service Form W-9, as
          applicable on or prior to any distribution or other payment to such Holder to permit any payment of any Payment Amount to be made without deduction or withholding of any US. backup withholding taxes or taxes imposed pursuant to Sections 1471
          through 1474 of the U.S. Internal Revenue Code, as amended (the&#160;&#8220;<u>Code</u>&#8221;).</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any portion of a Payment Amount that remains undistributed to the Holders on the date that is six months after the Rights Agent&#8217;s
          receipt of the applicable Payment Triggering Event Notice (including by means of uncashed checks or invalid addresses on the CVR Register) will be delivered by the Rights Agent to the Company or a Person nominated in writing by the Company (with
          written notice thereof from the Company to the Rights Agent), and any Holder will thereafter look only to the Company for payment of such Payment Amount (which shall be without interest).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If any Payment Amount (or portion thereof) remains unclaimed by a Holder on the date that is four years after the Rights Agent&#8217;s receipt
          of the applicable Payment Triggering Event Notice or the Payment Amount (or immediately prior to such earlier date on which such Payment Amount would otherwise escheat to or become the property of any governmental authority), then: (i) such
          Payment Amount (or portion thereof) will, to the extent permitted by applicable Law, become the property of the Company and will be transferred to the Company or a Person nominated in writing by the Company (with written notice thereof from the
          Company to the Rights Agent), free and clear of all claims or interest of any Person previously entitled thereto, and no consideration or compensation shall be payable therefor, and (ii) the CVRs to which such payment relate shall be deemed
          abandoned in accordance with Section 2.5 and shall no longer be deemed outstanding for any purpose (including for purposes of calculating a Holder&#8217;s Pro Rata Share). Neither the Company nor the Rights Agent will be liable to any Person in respect
          of a Payment Amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable Law. In addition to and not in limitation of any other indemnity obligation herein, the
          Company agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to the Company or a public official.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 2.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">No Voting, Dividends or Interest; No Equity or Ownership Interest.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CVRs will not represent any equity or ownership interest in the Company or any of its Affiliates. The sole right of the Holders to
          receive property hereunder is the right to receive Payment Amounts, if any, in accordance with the terms hereof.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors
          outside of the Company&#8217;s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. It is highly possible that there will not be any CVR Payment Amounts. Neither Company nor its
          Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto intend solely the express provisions of this Agreement to govern their contractual relationship with
          respect to the CVRs. This Section 2.4(c) is an essential and material term of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 2.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Ability to Abandon CVR.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">A Holder may at any time, at such Holder&#8217;s option or upon the failure to claim payment under Section 2.3(f), abandon all of such Holder&#8217;s remaining rights represented by CVRs by
        transferring such CVR to the Company or a Person nominated in writing by the Company (with written notice thereof from the Company to the Rights Agent) without consideration in compensation therefor, and such rights will be cancelled, with the
        Rights Agent being promptly notified in writing by the Company of such transfer and cancellation. No such notice to the Rights Agent shall be required in the case of abandonment due to the failure to claim payment under Section 2.3(f). Nothing in
        this Agreement is intended to prohibit the Company or its Affiliates from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 2.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Non-transferable.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted
        Transfer. The CVRs will not be listed on any quotation system or traded on any securities exchange.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center;"><font style="font-weight: bold;">ARTICLE 3</font> <br>
         <font style="font-weight: bold;">THE RIGHTS AGENT</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Certain Duties and Responsibilities.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the extent
          such liability arises as a result of the willful misconduct, bad faith or gross negligence of the Rights Agent (in each case as determined by a final non-appealable judgment of court of competent jurisdiction). Notwithstanding anything in this
          Agreement to the contrary, any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees paid by the Company to the Rights Agent during the 12 months immediately preceding the event for which recovery from
          the Rights Agent is being sought. Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including, without
          limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent will not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect
          to any action or default by any Person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the
          Company. All rights of action under this Agreement may be enforced (but shall not be required to be enforced) by the Rights Agent, any claim, action, suit, audit, investigation or proceeding instituted by the Rights Agent will be brought in its
          name as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may appear on the CVR Register.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 3.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Certain Rights of Rights Agent.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied
          covenants or obligations will be read into this Agreement against the Rights Agent.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent may rely and will be protected by the Company in acting or refraining from acting upon any resolution, certificate,
          statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in the absence of bad faith to be genuine and to have been signed or presented by or on behalf of the Company.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking or omitting any action hereunder,
          the Rights Agent may (i) rely upon an Officer&#8217;s Certificate and (ii) incur no liability and be held harmless by the Company for or in respect of any action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon
          such Officer&#8217;s Certificate.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent may engage and consult with counsel of its selection, and the advice or opinion of such counsel will, in the absence of
          bad faith, gross negligence or willful misconduct on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any permissive rights of the Rights Agent hereunder will not be construed as a duty.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this
          Agreement.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any loss, liability,
          damage, judgment, fine, penalty, cost or expense (each, a &#8220;<u>Loss</u>&#8221;) suffered or incurred by the Rights Agent and arising out of or in connection with the Rights Agent&#8217;s performance of its obligations under this Agreement, including the
          reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection in connection with the execution, acceptance, administration, exercise and
          performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been
          determined by a final non-appealable decision of a court of competent jurisdiction to have resulted from the Rights Agent&#8217;s gross negligence, bad faith or willful misconduct; provided that this Section 3.2(g) shall not apply to (i)&#160;income,
          receipt, franchise or similar Taxes, (ii)&#160;any Taxes imposed due to the Rights Agent&#8217;s connection with the jurisdiction imposing such Taxes (other than any connection caused solely by this Agreement or the Rights Agent performing, enforcing or
          receiving payments under this Agreement), or (iii)&#160;any Taxes imposed due to the failure of the Rights Agent to provide any form, document or certificate that would have reduced or eliminated the amount of such withholding taxes (&#8220;<u>Excluded
            Taxes</u>&#8221;).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In addition to the indemnification provided under Section 3.2(g), the Company agrees (i) to pay the fees of the Rights Agent in
          connection with the Rights Agent&#8217;s performance of its obligations hereunder, as agreed upon in writing by the Rights Agent and the Company on or prior to the date of this Agreement, and (ii) to reimburse the Rights Agent for all reasonable and
          properly documented out-of-pocket expenses, including all stamp and transfer Taxes (excluding any Excluded Taxes) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement, except that the
          Company will have no obligation to pay the fees of the Rights Agent or reimburse the Rights Agent in connection with any lawsuit initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the
          provisions of Section 2.3(b) or Section 3.2(g), if the Company is found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such suit.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability
          in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent will not be deemed to have knowledge of any event of which it was supposed to receive notice hereunder but has not
          received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection therewith, in each case, unless and until it has received such notice in writing.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to applicable Law, (i) the Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights Agent may
          buy, sell or deal in any securities of the Company or become peculiarly interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not
          the Rights Agent under this Agreement, and (ii) nothing herein will preclude the Rights Agent from acting in any other capacity for the Company or for any other Person.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or
          by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to the Company resulting from any such act, default,
          neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall perform, acknowledge and deliver or cause to be performed, acknowledged and delivered all such further and other acts,
          documents, instruments and assurances as may be reasonably required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement (except
          its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by the Company only.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent shall act hereunder solely as agent for the Company and shall not assume any obligations or relationship of agency or
          trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by the Company, including,
          without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (a) any guaranty of signature by an
          &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in substitution for, the foregoing; or
          (b) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent shall not be liable or responsible for any failure of the Company to comply with any of its obligations relating to any
          registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable regulation or law.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The obligations of the Company under this Section 3.2 shall survive the expiration of the CVRs and the termination of this Agreement and
          the resignation, replacement or removal of the Rights Agent.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 3.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Resignation and Removal; Appointment of Successor.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent may resign at any time by written notice to the Company. Any such resignation notice shall specify the date on which
          such resignation will take effect (which shall be at least 30 days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (x) the date so specified and (y) the appointment of a
          successor Rights Agent.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will have the right to remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date on
          which such removal will take effect. Such notice will be given at least 30 days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Rights Agent resigns, is removed or becomes incapable of acting, the Company will promptly appoint a qualified successor Rights
          Agent. Notwithstanding the foregoing, if the Company fails to make such appointment within a period of 30 days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or
          incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance of such appointment in
          accordance with this <u>Section 3.3(c)</u> and <u>Section 3.4</u>, become the Rights Agent for all purposes hereunder.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor
          Rights Agent in accordance with <u>Section 6.2</u>. Each notice will include the name and address of the successor Rights Agent. If the Company fails to send such notice within ten Business Days after acceptance of appointment by a successor
          Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of the Company.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Section 3.3, unless consented to in writing by the Majority of Holders, the Company
          will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Rights Agent will reasonably cooperate with the Company and any successor Rights Agent in connection with the transition of the
          duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent; but such predecessor Rights Agent shall not be required to make
          any additional expenditure or assume any additional liability in connection with the foregoing.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 3.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Acceptance of Appointment by Successor.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to the Company and to the resigning or removed Rights Agent
        an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the Rights Agent; <font style="font-style: italic;"><u>provided</u></font>, that upon the request of the Company or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all
        the rights, powers and trusts of such resigning or removed Rights Agent.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center;"><font style="font-weight: bold;">ARTICLE 4</font> </div>
      <div style="text-align: center;"><font style="font-weight: bold;">COVENANTS</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 4.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">List of Holders.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The Company will furnish or cause to be furnished to the Rights Agent, in such form as the Company receives from its transfer agent (or other agent performing similar services for
        the Company), the names and addresses of the Holders within 10 Business Days following the Record Date.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 4.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Prohibited Actions.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Unless approved by the Special Committee, the Company shall take no action for the principal purpose of (i) reducing the amount of any Payment Amounts payable under this Agreement
        or (ii) restricting the Company&#8217;s ability to pay any of the Payment Amounts hereunder. Unless approved by the Special Committee, the Company shall not grant any lien, security interest, pledge or similar interest in: (x) any Payment Amounts or
        proceeds from any Disposition or other Payment Triggering Event during the Term, or (y) any Legacy Assets during the Disposition Period.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Backstop Financing Statement.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">It is the intent of the Company for the distribution to the Holders of the rights to receive the Payment Amount in respect of any Disposition to be complete and irrevocable.
        Notwithstanding the foregoing, the form of financing statement on Form UCC-1 attached as <u>Exhibit A</u> hereto shall be filed within 10 Business Days from the Record Date for the purpose of establishing a first-priority security interest in the
        Payment Amounts, to the extent that the assignment of such rights hereunder is not deemed effective, complete, or irrevocable for any reason.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 4.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">CVR Committee; Efforts.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to Section 4.4(b), the Special Committee shall have the sole responsibility, authority, and discretion during the Disposition
          Period to (i)&#160;negotiate the terms of any Disposition, (ii)&#160;oversee the prosecution and settlement of any Claim(s), and (iii)&#160;oversee the execution of any Payment Triggering Event(s). The Special Committee will recommend to the Board of Directors
          approval of any Disposition Agreement negotiated by the Special Committee, and provided that such Disposition Agreement does require the Company to expend or risk its own funds or otherwise incur any financial liability in the performance of any
          duties under such Disposition Agreement following the closing of the transactions thereunder (such as indemnity obligations and any restrictions on the ability to conduct the Company&#8217;s business), the Board of Directors shall promptly cause the
          Company to execute and deliver such Disposition Agreement. For the avoidance of doubt, payments from the Interim Operating Amount shall not be considered Company financial liabilities for purposes of this Section 4.4. To the extent permitted
          under Nasdaq listing standards and applicable law, each member of the Special Committee will be entitled to receive reasonable compensation for their services and effort, and reasonable reimbursements for expenses, if any, provided that such
          compensation will not exceed an equivalent of $400&#160;per hour of service or effort by each such member of the Special Committee.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The responsibility and authority of the Special Committee set forth in Section 4.4(a) will not be revoked or modified at any time during
          the Disposition Period; <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, no provision of this Agreement will require the Company to expend or risk its own funds or otherwise
          incur any financial liability in the performance of any duties hereunder or in the exercise of any rights or powers, to the extent in excess of the Interim Operating Amount. The Special Committee and the Company&#8217;s Board of Directors will not owe
          fiduciary duties to the Holders (in their capacity as such) and will not have any liability to the Holders for any actions taken or not taken in connection with the matters set forth herein. Moreover, neither the Special Committee or any members
          thereof will be required to expend or risk his or her own funds or otherwise incur any financial liability in the performance of any duties hereunder or in the exercise of any rights or powers.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In furtherance of the authority granted to the Special Committee under Section 4.4(a), the Special Committee will be entitled during the
          Disposition Period to incur, and the Company shall pay any and all, fees, expenses and costs to manage, negotiate, settle and finalize the Claims and any audits under <u>Section 4.5</u> (the&#160;&#8220;<u>Incurred Fees</u>&#8221;); <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, the Incurred Fees may not exceed the Interim Operating Amount. Upon the expiration of the Disposition Period, to the extent the Interim Operating Amount
          exceeds the Incurred Fees, any such excess amount will be distributed to the Holders as a Payment Amount. For the avoidance of doubt, the Special Committee may not incur any fees, expenses or costs under this Section in excess of the Interim
          Operating Amount without the prior written approval of the Company&#8217;s Board of Directors.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to <u>Section 6.7</u>, the Holders will be intended third-party beneficiaries of the provisions of this Agreement and will be
          entitled to specifically enforce the terms hereof; <font style="font-style: italic;"><u>provided</u></font>, that under no circumstances will the rights of Holders as third-party beneficiaries pursuant to this <u>Section&#160;4</u> be enforceable by
          such Holders or any other Person acting for or on their behalf other than the Special Committee. The Special Committee has the sole power and authority to act on behalf of the Holders in enforcing any of their rights hereunder.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to <u>Section 4.4</u><u>(b)</u>, during the Disposition Period, the Company will, and will cause its Subsidiaries to, use
          commercially reasonable efforts to uphold the terms of all Disposition Agreements, including as applicable, effectuate the Disposition of Legacy Assets or Claims pursuant to such Disposition Agreement in accordance with its terms.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything contained herein to the contrary, the Company will not, and will not permit its Affiliates to: (i)&#160;amend any
          Disposition Agreement or waive any right thereunder, if such amendment or waiver materially and adversely affects the rights of the Holders to receive the CVR Payment Amounts hereunder, unless the Special Committee consents to each such amendment
          or waiver, which will not be unreasonably withheld, delayed, or conditioned, or (ii)&#160;assign any Disposition Agreement without the consent of the Special Committee, unless such assignee agrees to assume all payment obligations under, and agrees to
          be bound in writing to the terms of such agreement and this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Section 4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Copies of CVR Records; Audit Rights</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Holder shall have the right, at any time, to request in writing to receive copies of: (i) Payment Triggering Event Notices
          delivered to the Rights Agent, (ii) any Audit Reports delivered to the Rights Agent pursuant to Section 4.5(b), (iii) copies of material correspondence between the Company or its Affiliates and the Rights Agent, (iv) amendments to the Agreement
          effected pursuant to <u>ARTICLE 5</u>, and (v) the records of the Rights Agent setting forth the dates and amounts of all Payment Amounts delivered to the Rights Agent, whether by Celgene, the Company or an Affiliate of the Company. The
          requesting Holder(s) shall pay the reasonable out-of-pocket expenses of the Rights Agent (<font style="font-style: italic;">e.g.</font>, photocopying expenses, postage, etc.) incurred in responding to any such document requests.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall keep, and shall require its Affiliates to keep, complete and accurate books and records that may be necessary for the
          purpose of calculating the Payment Amounts payable under this Agreement. At the request of the Special Committee, the Special Committee shall have the right to appoint an independent accounting firm to perform, on behalf of all Holders, an
          inspection of such books and records for the sole purpose of determining the Payment Amounts payable hereunder. Upon at least ten Business Days&#8217; prior written notice from the Special Committee, such audit shall be conducted during regular
          business hours in such a manner as to not unnecessarily interfere with the Company&#8217;s normal business activities. Such audit shall not be performed more frequently than once per calendar year. If the audit reveals an overpayment, the Company shall
          be entitled to withhold such amount from future payments of Payment Amounts. If the audit reveals an underpayment, the Company shall promptly (and in any event within 30 days) remit such amount to the Rights Agent for distribution to the Holders.
          The Company shall pay the audit costs if the underpayment exceeds 5% of the aggregate amount owed with regard to the period of the audit; otherwise, the Special Committee requesting the audit shall bear such audit expenses. A copy of the results
          of any audit conducted under this Section 4.5(b) (an &#8220;<u>Audit Report</u>&#8221;) shall be provided to the Company and the Rights Agent within thirty (30) days from issuance by the auditor.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">ARTICLE 5 </div>
      <div style="text-align: center; font-weight: bold;">AMENDMENTS</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 5.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Amendments Without Consent of Holders or Rights Agent.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company, at any time and from time to time, may enter into one or more amendments to this Agreement for any of the following
          purposes, without the consent of any of the Holders or the Rights Agent (subject to Section 5.3), <font style="font-style: italic;"><u>provided</u></font>, that if any such amendment(s) (individually or the aggregate) materially impairs or
          adversely affects the rights of the Holders hereunder, such amendment shall also require the prior written consent of the Holders in accordance with Section 5.2:</div>
      <div>&#160;</div>
      <div>
        <div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; to evidence the appointment of another
            Person as a successor Rights Agent and the assumption by any successor Rights Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof;</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 72pt;"><font style="text-align: left;"> <br>
            </font></div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to evidence the succession of another
            Person to the Company and the assumption of any such successor of the covenants of the Company outlined herein in a transaction contemplated by <u>Section 6.6</u>;</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 72pt;"><font style="text-align: left;"> <br>
            </font></div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to add to the covenants of the Company
            such further covenants, restrictions, conditions or provisions for the protection and benefit of the Holders; <font style="font-style: italic;"><u>provided</u></font>, that in each case, such provisions shall not adversely affect the interests
            of the Holders;</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 72pt;"><font style="text-align: left;"> <br>
            </font></div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to cure any ambiguity, to correct or
            supplement any provision in this Agreement that may be defective or inconsistent with any other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement;<font style="font-style: italic;"><u> provided</u></font>, that in each case, such provisions shall not adversely affect the interests of the Holders;</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 72pt;"><font style="text-align: left;"> <br>
            </font></div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; as may be necessary or appropriate to
            ensure that CVRs are not subject to registration under the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations made thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws;</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 72pt;"><font style="text-align: left;"> <br>
            </font></div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; as may be necessary or appropriate to
            ensure that the Company is not required to produce a prospectus or an admission document in order to comply with applicable Law;</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 108pt;"><font style="text-align: left;"> <br>
            </font></div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; to cancel CVRs (i) in the event that any
            Holder has abandoned its rights in accordance with <u>Section 2.5</u> or (ii) following a transfer of such CVRs to the Company or its Affiliates in accordance with Section 2.2 and Section 2.6;</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 108pt;"><font style="text-align: left;"> <br>
            </font></div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(viii)</font>&#160;&#160;&#160;&#160;&#160;&#160; as may be necessary or appropriate to
            ensure that the Company complies with applicable Law; or</div>
          <div> </div>
        </div>
      </div>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 72pt;"><font style="text-align: left;"> <br>
            </font></div>
          <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"> <font style="text-align: left;">(ix)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to effect any other amendment to this
            Agreement that would provide any additional rights or benefits to the Holders or that does not adversely affect the legal rights under this Agreement of any such Holder.</div>
          <div> </div>
        </div>
      </div>
      <div style="text-indent: 72pt;"> <br>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Promptly after the execution by the Company of any amendment pursuant to this <u>Section 5.1</u>, the Company will (or will cause the
          Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <u>Section 6.2</u>.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 5.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Amendments with Consent of Holders.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In addition to any amendments to this Agreement that may be made by the Company without the consent of any Holder or the Rights Agent
          pursuant to <u>Section 5.1</u>, with the consent of the Majority of Holders, the Company and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of this
          Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Promptly after the execution by the Company and the Rights Agent of any amendment pursuant to the provisions of this <u>Section 5.2</u>,
          the Company will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <u>Section 6.2</u>.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 5.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Effect of Amendments.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Upon the execution of any amendment under this <u>ARTICLE 5</u>, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all
        purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of the Company which states that the proposed supplement or amendment is in compliance with the terms of this <u>ARTICLE 5</u>, the
        Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would
        adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement, amendment or other modification to this Agreement shall be effective unless duly executed by the Rights Agent.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">15</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center;"><font style="font-weight: bold;">ARTICLE 6</font> </div>
      <div style="text-align: center;"><font style="font-weight: bold;">MISCELLANEOUS</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Notices to Rights Agent and to the Company.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">All notices, requests and other communications (each, a &#8220;<u>Notice</u>&#8221;) to any party hereunder shall be in writing and delivered personally, by FedEx or other internationally
        recognized overnight courier service or, except with respect to any Notice from any Holder, by email. Such Notice shall be deemed given (a) on the date of delivery, if delivered in person or by e-mail (upon confirmation of receipt) prior to 5:00
        p.m. in the time zone of the receiving party or on the next Business Day, if delivered after 5:00 p.m. in the time zone of the receiving party or (b) on the first Business Day following the date of dispatch, if delivered by FedEx or by other
        internationally recognized overnight courier service (upon proof of delivery), addressed as follows:</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">if to the Rights Agent, to:</div>
      <div>&#160;</div>
      <div style="margin-left: 72pt;">American Stock Transfer &amp; Trust Company, LLC<br>
        6201 15th Ave<br>
        Brooklyn, NY 11219<br>
      </div>
      <div>
        <table class="DSPFListTable" id="z39370ed5cd294d8e970a17431d932775" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="width: 72pt;">
                <div><br>
                </div>
              </td>
              <td style="vertical-align: top; width: 72pt; text-align: left;">
                <div>Attention:</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div>Corporate Actions Group</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table class="DSPFListTable" id="z3bc9dc5368aa4265a800034135d33b3d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="width: 72pt;">
                <div><br>
                </div>
              </td>
              <td style="vertical-align: top; width: 72pt; text-align: left;">
                <div>E-mail:</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div>reorg_rm@astfinancial.com</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
         </div>
      <div style="text-indent: 36pt;">if to the Company, to:</div>
      <div>&#160;</div>
      <div style="margin-left: 72pt;">Catalyst Biosciences, Inc.</div>
      <div style="margin-left: 72pt;">611 Gateway Blvd.</div>
      <div style="margin-left: 72pt;">Suite 120</div>
      <div style="margin-left: 72pt;">South San Francisco, CA 94080</div>
      <div>
        <table class="DSPFListTable" id="zf471c46dc28b47668f0886950a36c4a1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="width: 72pt;">
                <div><br>
                </div>
              </td>
              <td style="vertical-align: top; width: 72pt; text-align: left;">
                <div>Attention:</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div>Nassim Usman</div>
                <div>Seline Miller<br>
                  </div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table class="DSPFListTable" id="z985871f2031e4af680d1e6b9fc54b111" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="width: 72pt;">
                <div><br>
                </div>
              </td>
              <td style="vertical-align: top; width: 72pt; text-align: left;">
                <div>E-mail:</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div>nusman@catbio.com</div>
                <div>smiller@catbio.com<br>
                  </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-indent: 72pt; margin-left: 72pt;"><br>
      </div>
      <div style="text-align: justify;">or to such other address as such party may hereafter specify for the purpose by notice to the other parties hereto.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Notice to Holders.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">All Notices required to be given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at
        such Holder&#8217;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the sending of such Notice, if any,<font style="color: #000000;"> and will be deemed given </font>on the
        date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other
        Holders.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Entire Agreement.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">As between the Company and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement,
        notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">16</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Successor Substituted.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Upon any consolidation of or merger by the Company with or into any other Person, or any conveyance, transfer or lease of substantially all of the properties and assets of the
        Company to any Person, the surviving Person or acquiring Person (as applicable) shall succeed to, and be substituted for, and may exercise every right and power of, and shall assume all of the obligations of the Company under this Agreement with
        the same effect as if such Person had been named as the Company herein.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Merger or Consolidation or Change of Name of Rights Agent.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to
        which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights
        Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, <font style="font-style: italic;"><u>provided</u></font>, that such Person would be eligible for appointment as a
        successor Rights Agent under the provisions of <u>Section 3.3</u>. The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for
        purposes of this <u>Section 6.5</u>.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Successors and Assigns.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of, the Holders, the Company and the Rights Agent and their respective successors
        and assigns. Except for assignments to its Affiliates and as provided in <u>Section 6.5</u>, the Rights Agent may not assign this Agreement without the Company&#8217;s prior written consent. Subject to Section&#160;5.1(a)(ii) and Section 6.4 hereof, the
        Company may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more of its Affiliates or to any Person with whom the Company is merged or consolidated,
        or any entity resulting from any merger or consolidation to which the Company shall be a party (each, an &#8220;<u>Assignee</u>&#8221;); <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, that
        in connection with any assignment to an Assignee, the Company shall agree to remain liable for the performance by the Company of its obligations hereunder (to the extent the Company exists following such assignment). The Company or an Assignee may
        not otherwise assign this Agreement without the prior consent of the Majority of Holders. Any attempted assignment of this Agreement in violation of this <u>Section 6.6</u> will be void <font style="font-style: italic;">ab initio</font> and of no
        effect.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Benefits of Agreement; Action by Majority of Holders.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Nothing in this Agreement, express or implied, will give to any Person (other than the Company, the Rights Agent, the Holders and their respective permitted successors and assigns
        hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Company, the Rights Agent, the
        Holders and their permitted successors and assigns. The Holders are intended third-party beneficiaries under this Agreement, but will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set
        forth herein, the Majority of Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to the performance of this
        Agreement by the Company, and no individual Holder or other group of Holders will be entitled to exercise such rights. Notwithstanding the foregoing, in the event of a bankruptcy of the Company, individual Holders shall be entitled to assert claims
        in bankruptcy and take related actions in pursuit of such claims with respect to any Payment Amounts that may be claimed by the bankruptcy estate of the Company or by any creditor of the Company.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">17</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Governing Law.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This Agreement and the CVRs will be governed by, and construed in accordance with, the Laws of the State of New York, (without giving effect to any rule or principle that would
        result in application of the law of any other jurisdiction) and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Jurisdiction.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated hereby, each of the parties
        hereto: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Supreme Court of the State of New York, County of New York, or, if under applicable Law exclusive jurisdiction is vested in the Federal
        courts, the United States District Court for the Southern District of New York (and appellate courts thereof); (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause
        (a) of this <u>Section 6.9</u>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party; and (e)
        agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <u>Section 6.1</u> or <u>Section 6.2</u> of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Waiver of Jury Trial.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Each of the parties hereto hereby irrevocably waives any and all right to trial by jury in any legal proceeding arising out of or related to this Agreement or the transactions
        contemplated hereby. Each party certifies and acknowledges that (i) no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the
        foregoing waiver, (ii) each party understands and has considered the implication of this waiver, (iii) each party makes this waiver voluntarily, and (iv) each party has been induced to enter into this agreement by, among other things, the mutual
        waivers and certifications in this <u>Section 6.10</u>.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Severability Clause.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any reason determined to be invalid,
        unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not
        be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this Agreement so as to effect
        the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible; <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be
        entitled to resign immediately upon written notice to the Company.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">18</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Counterparts; Effectiveness.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto were upon the
        same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become
        effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no
        party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication).</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Termination.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This Agreement will automatically terminate and be of no further force or effect and, except as provided in Section 3.2, the parties hereto will have no further liability
        hereunder, and the CVRs will expire without any consideration or compensation therefor upon the payment of all amounts potentially due under any Disposition Agreement entered into during the Disposition Period (if any) (the &#8220;<u>Term</u>&#8221;). The
        termination of this Agreement will not affect or limit the right of Holders to receive the Payment Amounts under Section 2.3(b) to the extent earned prior to the termination of this Agreement, and the provisions applicable thereto will survive the
        expiration or termination of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Section 6.14&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Force Majeure</font>.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Notwithstanding anything to the contrary contained herein, none of the Rights Agent, the Company or any of its Subsidiaries (except as it relates to the obligations of the Company
        under <u>Section 2.3(a)</u>) will be liable for any delays or failures in performance resulting from acts beyond its reasonable control including acts of God, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or
        malfunctions of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war or civil unrest.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.15</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Construction.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of limitation,
          but rather will be deemed to be followed by the words &#8220;without limitation.&#8221;</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and
          will not be referred to in connection with the construction or interpretation of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless
          otherwise specified. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly
          by the parties and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-style: italic;">Section 6.16</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Tax Treatment.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The Rights Agent agrees to treat (i)&#160;the distribution of the CVRs as a distribution of contractual rights governed by Section 301 of the Code and (ii)&#160;any Payment Amount as a
        contractual payment pursuant to the rights afforded by this Agreement to the Holder and not as a distribution by the Company in respect of Company common stock for U.S. federal, and, to the extent applicable, state and local income tax purposes.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">19</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed as of the day and year first above written.</div>
      <div>&#160;</div>
      <div>
        <table id="zbededb648952416bb125548db5f60b82" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td rowspan="1" style="width: 50%;">&#160;</td>
              <td colspan="2" rowspan="1">
                <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Catalyst Biosciences, Inc.</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%;">&#160;</td>
              <td rowspan="1" style="width: 5%;">&#160;</td>
              <td rowspan="1" style="border-bottom: medium none rgb(0, 0, 0); width: 45%;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;By:</div>
              </td>
              <td style="border-bottom: 2px solid rgb(0, 0, 0); width: 45%;">
                <div>&#160;<font style="font-family: 'Times New Roman',Times,serif;">/s/ Nassim Usman, Ph.D.</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 45%;">
                <div>&#160;Name: Nassim Usman, Ph.D.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 45%;">
                <div>&#160;Title: Chief Executive Officer</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
         </div>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td rowspan="1" style="width: 50%;">&#160;</td>
              <td colspan="2" rowspan="1" style="font-size: 12pt;">
                <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">
                  <div style="color: rgb(0, 0, 0); font-size: 10pt;">American Stock Transfer &amp; Trust Company, LLC</div>
                </div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%;">&#160;</td>
              <td rowspan="1" style="width: 5%;">&#160;</td>
              <td rowspan="1" style="border-bottom: medium none rgb(0, 0, 0); width: 45%;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;By:</div>
              </td>
              <td style="border-bottom: 2px solid rgb(0, 0, 0); width: 45%;">
                <div>&#160;/s/ Michael Legregin</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 45%;">
                <div>Name: Michael Legregin</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 45%;">
                <div>Title: Senior Vice President, Corporate Actions Relationship Management &amp; Operations</div>
              </td>
            </tr>

        </table>
      </div>
      <br>

      <div style="text-align: center;"><font style="font-weight: bold;"> </font>
        <div>[<font style="font-style: italic;">Signature Page to Catalyst Contingent Value Rights Agreement</font>]</div>
      </div>
      <div><br>
         </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ny20009756x1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 5.1</div>
    <div style="text-align: right; font-weight: bold;"> <br>
    </div>
    <div style="text-align: right; font-weight: bold;"> <img src="ny20009756x1_ex5-1image01.jpg"></div>
    <div style="text-align: right; font-weight: bold;"> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2ca52086566f434caf3a38b34573758d" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 75%; vertical-align: top;">
            <div style="text-align: justify;">July 24, 2023</div>
            <div>&#160;</div>
            <div style="text-align: justify;">Catalyst Biosciences, Inc.</div>
            <div style="text-align: justify;">611 Gateway Blvd. Suite 120</div>
            <div style="text-align: justify;">South San Francisco, CA 94080</div>
            <div>&#160;</div>
            <div style="text-align: justify;">Re:&#160; Catalyst Biosciences, Inc.</div>
            <div style="text-align: justify;">&#160;&#160;&#160; &#160; &#160; Registration Statement on Form S-3</div>
            <div>&#160;</div>
            <div style="text-align: justify;">Ladies and Gentlemen:</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="font-size: 8pt; font-weight: bold;">Orrick, Herrington &amp; Sutcliffe LLP</div>
            <div style="font-size: 8pt;">&#160;</div>
            <div style="font-size: 8pt;">51 West 52nd Street</div>
            <div style="font-size: 8pt;">New York, NY 10019-6142</div>
            <div style="font-size: 8pt;">&#160;</div>
            <div style="font-size: 8pt;">+1 212 506 5000</div>
            <div style="font-size: 8pt;">&#160;</div>
            <div style="font-size: 8pt; font-weight: bold;">orrick.com</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">We have acted as counsel to Catalyst Biosciences, Inc., a Delaware
      corporation (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), and you have requested our opinion in connection with the filing of a Registration Statement on Form S-3 (the &#8220;<font style="font-weight: bold; font-style: italic;">Registration Statement</font>&#8221;) with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission&#8221;</font>), including a related prospectus filed
        with the Registration Statement (the &#8220;<font style="font-weight: bold; font-style: italic;">Prospectus</font>&#8221;), covering the registration of up to 1,240,442,745 shares (the &#8220;<font style="font-weight: bold; font-style: italic;">Shares</font>&#8221;) of common stock, par value $0.001
      per share (the &#8220;<font style="font-weight: bold; font-style: italic;">Common Stock</font>&#8221;) of the Company, consisting of (i) 6,266,521 shares of Common Stock and 123,400,000 shares of
      Common Stock issuable upon conversion of 12,340 shares of the Company&#8217;s Series X Convertible Preferred Stock, par value $0.001 per share, to be beneficially owned by GNI USA, Inc., a Delaware corporation (&#8220;<font style="font-weight: bold; font-style: italic;">GNI USA</font>&#8221;), following the transfer by GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;<font style="font-weight: bold; font-style: italic;">GNI
        Japan</font>&#8221;), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;<font style="font-weight: bold; font-style: italic;">GNI HK</font>&#8221;), to GNI USA prior to the closing of the transactions contemplated by the Business Combination Agreement (as defined below), previously issued pursuant to that certain Asset Purchase Agreement, dated December 26, 2022 and as amended on March 29,
        2023 (the &#8220;<font style="font-weight: bold; font-style: italic;">F351 Agreement</font>&#8221;), by and among the Company and GNI Japan and GNI HK, (ii) 953,821,796 shares of Common Stock issuable to GNI USA pursuant to the Business Combination Agreement, dated December
        26, 2022 (the &#8220;<font style="font-weight: bold; font-style: italic;">Business Combination Agreement</font>&#8221;), by and among the Company, GNI USA, the individuals listed on Annex A thereto (the &#8220;<font style="font-weight: bold; font-style: italic;">Minority Holders</font>&#8221;), and (iii) 156,954,428 shares of Common Stock to be issued to the Minority Holders pursuant to the Business Combination Agreement, and resale of the Shares by certain selling
        securityholders (the &#8220;<font style="font-weight: bold; font-style: italic;">Selling Securityholders</font>&#8221;) named in the Registration Statement, which may be offered and sold from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Securities Act</font>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify;">All of the Shares are being registered on behalf of the Selling Securityholders.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">In connection with this opinion, we have examined and relied upon the Registration Statement, the Prospectus, the Company&#8217;s certificate of incorporation,
      as amended and bylaws, as amended, each as currently in effect and the originals, or copies identified to our satisfaction, of such corporate records of the Company, certificates of public officials, officers of the Company, and other persons, and
      such other documents, agreements and instruments as we have deemed relevant and necessary for the basis of our opinions hereinafter expressed. In such examination, we have assumed the following: (a) the authenticity of original documents and the
      genuineness of all signatures; (b) the conformity to the originals of all documents submitted to us as copies; and (c) the truth, accuracy, and completeness of the information, representations, and warranties contained in the records, documents,
      instruments, and certificates we have reviewed.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: right;"><img src="ny20009756x1_ex5-1image01.jpg">
      <div><br>
      </div>
      <div style="text-align: left;">July 24, 2023<br>
      </div>
      <div style="text-align: left;">Page 2<br>
      </div>
      <div style="text-align: left;"><br>
      </div>
    </div>
    <div style="text-align: justify;">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares have been duly authorized, validly issued, fully paid and
      nonassessable.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Our opinion set forth in the immediately preceding paragraph is subject to (i) the effects of bankruptcy, insolvency, fraudulent conveyance,
      reorganization, moratorium and other similar laws relating to or affecting creditors&#8217; rights generally, (ii) general equitable principles (whether considered in a proceeding in equity or at law) or (iii) an implied covenant of good faith and fair
      dealing. Our opinion is subject to the qualification that the availability of specific performance, an injunction or other equitable remedies is subject to the discretion of the court before which the request is brought.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Our opinions herein are limited to the General Corporation Law of the State of Delaware, and the federal laws of the United States of America. This opinion
      is limited to such laws as are in effect on the date hereof. Without limitation, no opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Our opinions are limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinions are
      based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion
      expressed herein.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption
      &#8220;Legal Matters&#8221; in the Registration Statement and the Prospectus. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, or the Rules and
      Regulations of the Commission promulgated thereunder, nor do we thereby admit that we are &#8220;experts&#8221; within the meaning of such term as used in the Securities Act with respect to any part of the Registration Statement, including this opinion letter as
      an exhibit or otherwise.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Very truly yours,</div>
    <div><br>
    </div>
    <div><u>/s/ Orrick, Herrington &amp; Sutcliffe LLP</u></div>
    <div><br>
    </div>
    <div>ORRICK, HERRINGTON &amp; SUTCLIFFE LLP
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ny20009756x1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exhibit 23.1</div>
  <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
  </div>
  <br>
  <div style="text-align: center; color: #000000; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
  <div></div>
  <div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000;">We consent to the reference to our firm under the caption &#8220;Experts&#8221; and to the use of our report dated March 30, 2023, with respect to the consolidated financial statements of Beijing Continent
      Pharmaceuticals Co., Ltd. incorporated by reference in the Registration Statement (Form S-3) and related Prospectus of Catalyst Biosciences, Inc. for the potential resale of up to 1,240,442,745 shares of its common stock.</div>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; color: #000000;">/s/ Ernst &amp; Young Hua Ming LLP</div>
  <div style="text-align: justify; color: #000000;">Beijing, The People&#8217;s Republic of China</div>
  <div style="text-align: justify; color: #000000;">July 24, 2023</div>
  <div style="text-align: justify; color: #000000;"> <br>
  </div>
  <div style="text-align: justify; color: #000000;">
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ny20009756x1_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="text-align: right; font-weight: bold;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 23.2</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
  <div><br>
  </div>
  <div style="text-align: justify;">We consent to the incorporation by reference in this Registration Statement of Catalyst Biosciences, Inc. on Form S-3 to be filed on or about July 24, 2023 of our report dated March 30, 2023, on our audits of the
    financial statements as of December 31, 2022 and 2021 and for each of the years then ended, which report was included in the Annual Report on Form 10-K filed<font style="font-style: italic;">&#160;</font>March 30, 2023. Our report includes an explanatory
    paragraph about the existence of substantial doubt concerning the Company&#8217;s ability to continue as a going concern. We also consent to the reference to our firm under the caption &#8220;Experts&#8221; in this Registration Statement. <br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify;">/s/ EisnerAmper LLP</div>
  <div><br>
  </div>
  <div style="text-align: justify;">EISNERAMPER LLP</div>
  <div style="text-align: justify;">Philadelphia, Pennsylvania</div>
  <div style="text-align: justify;">July 24, 2023
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>ny20009756x1_ex107.htm
<DESCRIPTION>FILING FEES TABLE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">


  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 107</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">Calculation of Filing Fee Tables</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">Form S-3</div>
    <div style="text-align: center;">(Form Type)</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Catalyst Biosciences, Inc.</div>
    <div style="text-align: center;">(Exact Name of Registrant as Specified in its Charter)</div>
    <div style="text-align: center;"><u> <br>
      </u></div>
    <div style="text-align: center;"><u>Table 1: Newly Registered and Carry Forward Securities</u></div>
    <div style="text-align: center;"><u> <br>
      </u></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7a4e917eb8dd4b778b3b5f07ae04c38a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="border-bottom: 2px solid #000000; border-left: 2px solid; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 7.38%;">&#160;</td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 5.79%;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Security<br>
              Type</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 6.45%;">
            <div style="text-align: center;">Security</div>
            <div style="text-align: center;">Class</div>
            <div style="text-align: center;">Title</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 7.94%;">
            <div style="text-align: center;">Fee</div>
            <div style="text-align: center;">Calculation<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>or Carry<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>Forward<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>Rule</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 9.86%;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Amount<br>
              Registered</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 7.2%;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Proposed<br>
              Maximum<br>
              Offering<br>
              Price Per<br>
              Unit</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 12.65%;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Maximum<br>
              Aggregate<br>
              Offering<br>
              Price</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 7.75%;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Fee<br>
              Rate</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 8.88%;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Amount of<br>
              Registration<br>
              Fee</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 5.88%;">
            <div style="text-align: center;">Carry<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>Forward</div>
            <div style="text-align: center;">Form<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>Type</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 5.88%;">
            <div style="text-align: center;">Carry<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>Forward<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>File</div>
            <div style="text-align: center;">Number</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 6.35%;">
            <div style="text-align: center;">Carry<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>Forward</div>
            <div style="text-align: center;">Initial<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>Effective<font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>Date</div>
          </td>
          <td style="border-bottom: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: bottom; width: 7.98%;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Filing Fee<br>
              Previously<br>
              Paid In<br>
              Connection<br>
              with Unsold<br>
              Securities to<br>
              be Carried<br>
              Forward</div>
          </td>
        </tr>
        <tr>
          <td colspan="13" style="width: 100%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Newly Registered Securities</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.38%; vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
            <div style="font-family: 'Times New Roman',Times,serif;">Fees to Be</div>
            <div style="font-family: 'Times New Roman',Times,serif;">Paid</div>
          </td>
          <td style="width: 5.79%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Equity</div>
          </td>
          <td style="width: 6.45%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Common Stock, par value $0.001 per share</div>
          </td>
          <td style="width: 7.94%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Other</div>
          </td>
          <td style="width: 9.86%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">1,240,442,745 (1)</div>
          </td>
          <td style="width: 7.2%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">$0.4181 (2)</div>
          </td>
          <td style="width: 12.65%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">$518,629,111.68&#160; (2)</div>
          </td>
          <td style="width: 7.75%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$110.20 per</div>
            <div style="text-align: center;">$1,000,000</div>
          </td>
          <td style="width: 8.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#160;$57,152.93</div>
          </td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.35%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.98%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.38%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fees</div>
            <div style="text-align: center;">Previously</div>
            <div style="text-align: center;">Paid</div>
          </td>
          <td style="width: 5.79%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 6.45%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 7.94%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 9.86%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 7.2%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 12.65%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 7.75%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 8.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.35%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.98%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td colspan="13" style="width: 100%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Carry Forward Securities</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.38%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Carry</div>
            <div style="text-align: center;">Forward</div>
            <div style="text-align: center;">Securities</div>
          </td>
          <td style="width: 5.79%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 6.45%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 7.94%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 9.86%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 7.2%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 12.65%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 7.75%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 8.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 6.35%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 7.98%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.38%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="width: 30.04%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Total Offering Amounts</div>
          </td>
          <td style="width: 7.2%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 12.65%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">$518,629,111.68&#160; (2)</div>
          </td>
          <td style="width: 7.75%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 8.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#160;$57,152.93</div>
          </td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.35%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.98%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.38%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="width: 30.04%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Total Fees Previously Paid</div>
          </td>
          <td style="width: 7.2%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 12.65%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.75%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.35%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.98%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.38%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="width: 30.04%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Total Fee Offsets</div>
          </td>
          <td style="width: 7.2%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 12.65%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.75%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#8212;</div>
          </td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.35%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.98%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.38%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="width: 30.04%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Net Fee Due</div>
          </td>
          <td style="width: 7.2%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 12.65%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.75%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">&#160;$57,152.93</div>
          </td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 5.88%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.35%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.98%; vertical-align: bottom; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 3.5%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(1)</div>
          </td>
          <td rowspan="1" style="width: 84.7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">The shares of common stock will be offered for resale by the selling stockholders pursuant to the prospectus contained in the registration statement to which
              this exhibit is attached. The registration statement registers the resale of an aggregate of 1,240,442,745 shares of the registrant&#8217;s common stock. Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the
              shares of common stock being registered hereunder include such indeterminate number of shares of common stock as may be issuable upon stock splits, stock dividends, or other distribution, recapitalization or similar events.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.5%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(2)</div>
          </td>
          <td rowspan="1" style="width: 84.7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">This estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering
              price per share and maximum aggregate offering price are based upon the average of the high and low sales prices of the registrant&#8217;s common stock on July 19, 2023, as reported on The Nasdaq Capital Market.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo_catalystbiox1.jpg
<TEXT>
begin 644 logo_catalystbiox1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( /("_@,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M3E*3;E*3<I2;W;;NVWU;=S^B$E%*,4DDK)))));)):)+L@HHHI#"O@+]J_\
M:UN_AM>'X>_#.YL9/&2H6\2:Y-;I?Q>%XYH ]K86-O-NL[C7I1)'=3O=Q7=G
MIUL(X)+2YN[MCIOL7[47Q[MO@EX&<:9-%)X]\31W%CX3M&2.861552]\17D,
MH:,VFDI*IMHIHYDOM3DM+9H);,7\EM^$=Y>7>HW=UJ&H75Q?7]]<SWE[>WDT
MES=WEW=2M/<W5U<3,\UQ<7$SO+/-*[R2RNSNS,Q)^;SS-989?5,--QKR2=6I
M%ZTH/51B^E2:UOO&#36LDX_T?X(>%='B&I_K9Q'A(ULDPU2=+*\OQ$.:CFN*
MIMQJXC$4YKEJX#"2O3C3LX8K%1G"H_98:K2K]WJ7Q=^*NKR2RZG\2O'EZTS[
MW6?Q;KK1;L$ )!]N$,:J&*HD<:(BDJBJO%?IS_P3R_X*&?$WP#\3?!_P@^+W
MC#5O&OPI\;ZS8^&;'4?%>HSZMK7@#6M6:VTO0;VPU[4II+T>%/MHL;#5=%O;
MQM,T>QFEUG2ELI;:^M=6_(*@$@@@D$'((X((Z$'L14<%\=<1\"<08#B'(LRQ
M="OA,30JXG#1Q-6.%S/"TZD95\!CZ2DX5\-B::E2G&I"3I\RJTG"M"G./]'\
M<^&'!G'W"V9\*YUD65O"8["5Z.%Q%/+\+#%93BYTI0PV99;5A3A/#8O!U.2K
M3E3G"-10="LIT*E2G+_0 HKX_P#V$_C^/VC_ -FGP#XYO[S[7XPTBV;P/\0F
M9M\Y\9^%X+:VO=0N2EO;0"?Q+IDVD^+3#:QFWM$U]+)79[:0+]@5_M1P_GF
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW;YV:DY26K2_KY_U;T&HQ>S?]?(_L%_XB /^"=W_ $,?Q7_\-?J?_P G4?\
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M<Z6?Q?M-.CT_2]#U:*X>/1O#OBC2+2.'Q2\VG:9JVD1>(+>]\1^(Q3Z-6?\
M7W?UJ#CI>+NOQ7]?@?T%>*_$=AX.\+^)/%VJI<R:7X6T#6/$>I1V4:37CV&B
M:=<ZG>):12RP12W+6]K(L$<D\*/*45Y8U)<?AI_Q$6_L&_\ 0I_M(?\ AO\
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MXG\7_##Q'?R36+6.FV$5SJ6JW7@3Q9=O?6UC8V_[G1/%OB[5[V3R-*C"T?\
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M@-_R0WX,_P#9*/AW_P"HAH]>KUY1\!O^2&_!G_LE'P[_ /40T>O5ZL@****
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M;?\  N?V5QR1S1I+$Z2Q2HLD<D;*\<D;J&1T=25='4AE92592""0:?7Y:_\
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MEUO:![*&U_6ZHX8X888H;>..*"*-(X(H55(8X44+''$B (D:(%5%0!54 *
M!4E4E96[$MW;?<****8BAJNE:7KNF:CHFMZ;8:QHVKV-WIFK:1JMG;ZAIFJ:
M;?P26M]I^HV%W'-:WMC>6TLMO=VES%+;W$$DD,T;QNRGQWX'_LU? ;]FS3_%
M6E? CX6>$OA?IWC;Q)<^+/$]IX6L&M(M3UJY#*I/FRSM9Z5I\;R0Z)X>L&M?
M#WAZWFN+?0M+TZ"XGCD]QHH **** "BBB@#_ #U/^"S/_*3#]J3_ +#OP_\
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M/RDUSNQ'/<&"V/G1K>Q)Y-X!\%ZAX]\2V6@6.Z*.0FXU*]V%TT_3867[3=.
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MXZKBN>K@Z*DDG)))/4GDG\:5'>-TDC=HY(V5XY$8HZ.A#*Z,I#*RL 58$$$
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M];_"[P%=W-LR7$?@SP6Z:GXNU#3;G=LGTSQ+XOO=/TJZ4J6CU'X=,H*C=O\
MZ9J4%9>NHYN[] HHHJB3_.X_;<^&7B/_ ()^_P#!1OQLO@"W30T^'7Q<\/\
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M_DT/]E;_ +-O^!W_ *K'PO7\,G_!9G_E)A^U)_V'?A__ .J@^'M?W-_L;_\
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MLPCG1RS#RNFJ3:Y\34C>RKXIQC.?6$(TJ-Y>RYI%%* 6(5069B J@$DDG
MY))X ')-?I]^S!_P3T\0>-FT_P ;?'&WU#PIX0+PW5AX)#26/BKQ)"-DJG6"
M-MQX8TBXSY,D!\GQ)<QBX$4>BJUEJ<WZL?%'RE^SQ^R]\1OVB=;$/AVV_L;P
MA87<=OXB\<ZG;R-I&EC$<LUI8Q!H7UO6Q;R))%I%G+'L,UL^I7FEVEPEY7]
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M.CQQEV"H*G1RK.<3.-+#<04Z-&*ITL'G5:4</F34:<:><SI8F4JU7-ZGL?\
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M_#=^$/\ Y3T?\*&^!O\ T1GX4?\ AN_"'_RGHY9?S/[O^#Y?GW8<T?Y5]_\
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MN?\ =MG_ +WVL_\ EY_7\I:^"7K_ )']6E%%%:$!117*-X[\$+XV7X:MXO\
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M#2K".*9YM:TC3&CB>6.,5_:)2A>UG?3O?8<][IIW"O\ /4_X+,_\I,/VI/\
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M_P#GL4?\.1/^"H'_ $;'_P"9H_9[_P#GL4^9_P C_'_(GE7\Z_#_ #/[M_\
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M1S=W96[U:[61-'TA'"S7DRC!FF(RT%C Q4W%P1W$40>9T2MCQCJOBO3-./\
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M;84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /.TH_XAM/V0_P#HM?[2'_@V^&/_ ,[2CW_+^K?\'\?(/<\_ZM_P?Q\CA?\
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M#3UTK_A'/#?AU42Y7Q)>&\^UK=LS0VWD&$+*)?=OVR/^30_VJ?\ LV_XX_\
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MDIX.G\-07*7@U5',[7I\2P- 8,",6THDR73'YN_\1+?P/_Z-F^*W_A7>$/\
MXU7AG_!S7_R,W['7_8"^./\ Z</A57E7_!)?_@DO^S'^W!^S'KGQA^,.N?%W
M3?%6F_%WQ5X%M[?P+XJ\-Z+HQT;1?#?@K5K266TU;P7XANFOVNO$-\L\ZWR0
MO"ELB6T;1N\L-RYFE;^K?U\_2VBC'E3=_/[[?U\_(^R/^(EOX'_]&S?%;_PK
MO"'_ ,:H_P"(EOX'_P#1LWQ6_P#"N\(?_&J]T_XATOV#?^AL_:0_\.!X'_\
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M_I951V7HOR)>[MM=V/\ -$_;P_Y/B_;,_P"SK?VB/_5O>,*_TNZ_S1/V\/\
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ML=1T^[A;Y9K6\LYYK:XB;Y9(I'0\&OQ/^$W_  0)_8_^#/Q6^'/QA\'?$_\
M:</BGX8>//"WQ"\.6NJ>,_A;<Z--K'A'7;+7].LM5MK;X,V5]=:/<W-A%:ZE
M;0ZC:W-S823P)>PR2"98<7S)KRO_ %Z?EYEJ2Y7%_+^M.NI^X=?B=_P< ?\
M*.[Q'_V5?X7_ /ISOJ_;&OQ._P"#@#_E'=XC_P"RK_"__P!.=]52V?H_R)CN
MO5?F?E+_ ,&TG_)<OVF/^R4>$O\ U+Y*_L+K^/3_ (-I/^2Y?M,?]DH\)?\
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M*O\ 0KK_ #U/^",W_*3#]EO_ +#OQ _]5!\0J_T*ZB&S]?T14]UZ?JS\./\
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M?YHG[>'_ "?%^V9_V=;^T1_ZM[QA7^EW6=/K\OU+EM#T_1'Y"_\ !=66*/\
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MRE_X7'Q>_P#G&4?\0WG[<7_15/V4O_"X^+W_ ,XRB\_Y5_7S\_S[,+0_F?\
M7R\_S[,_HD_X?,_\$S_^CI-"_P##?_%__P"=]7I_P9_X*9_L-_M!_$GPW\(/
M@]\>])\:_$;Q=_;'_".^&;;P?\1]+GU+^P-!U3Q/J^R_U[P=I6DP?8]"T74]
M0;[7?P>:EHT,'FW,D,,G\QG_ !#>?MQ?]%4_92_\+CXO?_.,K[8_X)U?\$3/
MVJOV1?VR/@]^T-\2/'_[/NM^"_A]_P +!_MG2_!'BKXC:EXHNO\ A+/A9XW\
M#Z=_9=EKWPI\-:3-Y.K>);&XO?M>MV7EZ=%=RP?:;F.&TG:<[JZTZZ/R\_/^
MK,34+.S>VG]6\_S[,_J)KYO_ &R/^30_VJ?^S;_CC_ZK'Q17TA7S?^V1_P F
MA_M4_P#9M_QQ_P#58^**LF.Z]5^9_!5_P2J_Y2(_LE_]E7T[_P!-FJ5_HRU_
MG-?\$JO^4B/[)?\ V5?3O_39JE?Z,M1#9^OZ(J>Z]/U9_"K_ ,%L_P#@GN/V
M3?CB/C/\,]"6R_9_^.VKW]]I]EIE@]OI/PX^)4B2:EXA\# 0!K&PTC6T6[\4
M^![2/[#%'IZZ_P"'=,TY+#P:+JZ_;+_@A7_P4&/[17P?/[,GQ0UIKKXT_ O0
M+5?#.H7S)]K\>_!ZR>TTK2+UYP^Z\U_P%-/8^&==DEABGO=&N/"NK27&K:K<
M^([NW_7[]IO]G7X??M6_ [Q_\"/B99M/X:\<Z0]I%J-NJG5/#.O6CK>^'?%F
MB2,5$>K^'-8@M-4M$D8VEZ()=,U.&ZTJ^OK.X_SV=0LOC_\ \$T/VRC%YD7A
M_P",G[/?CN.XM;F,W<GA[Q5I$D D@G78]A>:EX%^)'@[4MD]NSV%]=^&]?GL
M[E=-U'SH[9/W976SW7Y_YK_(:]Y6>ZV?]?<_DS_2@KY2_;P_Y,=_;,_[-2_:
M(_\ 50^,*Z/]E']ICX??M=_ ?P%\>/AQ<H='\7Z8O]KZ))<+/J7@[Q98A;?Q
M-X-UK]U;NNI>']4$MJ+AK>"#5K V&NZ<LNDZKI]S/SG[>'_)CO[9G_9J7[1'
M_JH?&%:;D+=>J_,_B!_X(S?\I,/V6_\ L._$#_U4'Q"K_0KK_/4_X(S?\I,/
MV6_^P[\0/_50?$*O]"NHAL_7]$5/=>GZL_DM_P"#FME_X2C]CM<C<-!^.#%<
MC<%;4/A8%)'4!BK $\$JP'0U]A?\&W-I"G[%/Q;OE#?:+C]J3Q=:2DL2IALO
MA-\&)H %Z!@]_<%FZL"H/W17P)_P<M_\ER_9G_[)1XM_]2^.OO[_ (-NKB%O
MV)?BS:+(#<0?M3^,;B6+#92&Z^$OP5B@D+$;2)'L[E0 Q8>42P4,A87QOT_R
M'_R[_K^8_H-HHHJS,**** "BBB@#^2[_ (.:_P#D9OV.O^P%\<?_ $X?"JMK
M_@BE_P %"/V._P!EK]D7Q%\-_CU\:M,^'OC6]^-_C+Q7:Z%>>%O'NM2R^']3
M\*> -.L=1%WX9\*ZUIRI<7FCZE ('NUND-JSR0)')"\F+_P<U_\ (S?L=?\
M8"^./_IP^%5?F5^Q'_P2$^/7[=GP?U'XS_#/XB_"+PIX>TSQSK7@*;3/'5]X
MRMM9?5-$TGP_K%S=Q1Z!X/UZQ-A+;^([2.!GO5N#-#<B2WC01/)FVU-V5WI^
MAJK."OHO^"?UD_\ #YG_ ()G_P#1TFA?^&_^+_\ \[ZC_A\S_P $S_\ HZ30
MO_#?_%__ .=]7\_'_$-I^UY_T6O]F_\ \&WQ._\ G:4?\0VG[7G_ $6O]F__
M ,&WQ._^=I1>?\J_KY^?Y]F*T/YG_7R\_P ^S/Z!_P#A\S_P3/\ ^CI-"_\
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M/C#^R7^V5^QCK^G^(?BC\)OBI\&]0T34+"ZT7XBZ5Y\GAZPUGS?-T\Z%\5?
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M^87;Y:6#QJ5/!YE)\L*:CA<9.I"EA*RJ_P []%!!!((P1P0>H/H:*_Q+/]1
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MHHHK0@**** "OF_]LC_DT/\ :I_[-O\ CC_ZK'Q17TA7S?\ MD?\FA_M4_\
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M]A>%/&'Q-^'FMW//G_VKX_T7PIXD\,0]<>2+3X;>+78D<2,@S\P!Y'_@V?\
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MJ@BDUK0-+^)=]K\2./WC216/B3PV\BL-B+-$4^9Y,9K2=EM_P+_F:/6%WO\
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MMM8:1\1=4M;=8KSQ'\*[RX>&/4XM5,;ZI<^"')\3>&C)>6<4?B'1=*'BF_\
MV!K^#C]K3_@AQ^V9^SKK&HZM\+O#5Y^TI\-(9FGTKQ)\+M.FG\?6D'F(MM;Z
M_P#"V.>[\4#5BY=MW@O_ (3/2UMXDN;G4K":;[##\Y:'_P %&O\ @I3^SV\7
MP_?]H7XV^$+OPO:MI"^%/B59Q:]JNBVHE#)8SZ;\3]"UK4K7[)Y0MK%+F-9-
M.M(QI]B;>S06X7,UI)?-?U;[ON*<$]8M6\_Z_/4_T4G=(U9W941%9W=V"JB*
M"69F) 55 )9B0  23BOYKO\ @KS_ ,%B? G@SP+XH_9D_94\7Z#X]\?^.]"U
M7PW\2/BEX5U>WUCPU\.O#FL6UQI>K:#X7US2;B6SU/X@ZC:2W-I/J&GW<MMX
M)@=W69O%!B30OYP]>_:)_P""@7[:.M:EX-NOB;^TK\>[SQ&7FO\ X;>$;[QM
MK_A^[C*[9&C^&/@F-?#%I:*A/F+:^'+>TC3<7"IDU^EO[(__  ;[?M-?%36M
M)U[]IR\L?V?/ALD\%SJ.AV^IZ-XI^+6O6&;6X^RZ3I>D7&J^&/"@O[=[FT?5
M/%&K3:QH-ZB23^!=6CWPTG)RTBGZ_P!;?>'*HZR:]/ZW_KT/(/\ @B;^PKK7
M[4/[3.@?%_Q;X>NV^ W[/^N67BS7=6O+-AHOBWXD:.UIJG@KX?6=Q-BWU&>U
MU"73?%_BRR2&^M8/#6GPZ3K261\8:')=?W@UY)\#/@9\+_V;_A?X7^#OP=\+
MVGA'P'X1M'M]-TVW>6XN;FYN)6N-1U?5]1N&DO-6UO5KR26]U/4[V62XN;B0
M\I"D44?K=5&/*O/J3)W?ET/Y ?\ @H]_P65_:T^%G[:TW@KX-Z7K'P?\%?L]
MZ_<:-?>!?B-X9C8_&J\DVF_\1>-=*D,-Z?A]XCTJ2%_A['H6L6-_+X=O+;QS
M9:WI^M:SI\'AS]A/V*_^"SW[)?[65MHGACQ-XAM?@)\:+];>TG^'WQ%U.WL]
M"UK5I3;PB'P)\09X[+P]X@6\O+F*TTO1]5;P]XPU"Y,D5GX:NX8?MDOT[^VK
M_P $_OV>/V[/!D?A_P"+WAZ73_%VC6S1>"OBMX66SL/B!X.;SGN/LEKJ4]K<
MV^L>'+J:6?\ M'PMKEO?:1/]IGO;&+3-=2QUJQ_D$_:J_P""'G[;'[/&I:KJ
M/@/PA+^TE\-[9VDT[Q7\)K&6]\7&U>X>&VAUOX4&XN_&5OJS(HN+J#PI%XVT
M6S@=&D\0L_FQQ)\R=_B3_K;I_5QKEDDMG^?^?IOV/[UP00"""" 00<@@\@@C
M@@CH:6O\U7P9^U7^W!^RI++\._"_QH^/WP931"\,GPWU+7O%>B:;HCS;C)M\
M ^)"=-TFXE)+/)'HUM.[*K%RR(5]6\1?\%3_ /@I%\2Y8=(N/VIOBT]W>QP6
M%M:> 1I'@?4KDQRF6)+4_#G0_#M^]X[9$EQ QO;B(>3-+)"/+H]HNJ?Y_P"0
M<CZ-6[_U_F?WQ?'G]I;X$?LQ^$9_&WQV^*'A/X<Z''#/+91ZYJ48US7I+9=\
MECX6\,VOVCQ#XIU,+\W]G>'],U&\"!IGA6&.21/\^[]NG]K+QS_P4%_:IUGX
MH1Z%JD5KK$^D?#OX-_#VUB.HZMI'@^TU"X@\+>'H[>R-R]_XDU_5]6OM<U>&
MTDNTF\3>(;^STICIT>GV\7H7PW_X)K?\%(?VLO%-UXCF^"7Q;N+[7+RTNM>^
M)GQ[N-1\$0W:7\HB;7;G7OBA<Z?XA\7PP+F:[?PS:>)]4$2$QV<SE(V_J!_X
M)Q?\$5_A=^QQJVE_%_XO:SI/QI^/]E%;W&B7<6F21_#SX8:@$#3W/@FQU2-=
M0UWQ#%,66U\;Z[9Z9=VL"0/HGAWP[>B[NKQ/FG96LM_Z?7Y#7+"[O=]/ZU^_
M[C[@_P""='[*I_8V_9$^%7P5U)+!_&UK87?BSXG7VGK&8K[XA^+KEM7UZ#[5
M$[1ZC%X;AEL/!FG:HHB_M'1_#.FW;00-*T2=3^W'^RAX9_;2_9I^(?P&\03V
MNF:EKMG#K'@3Q/<VR7)\(?$+06:]\+:^N8)YTL_M7FZ/XA6Q6._O?"NKZ]I=
MK<6\E^)D^MZ*NRM;I:WR(N[WZWO\S_-<^#/Q5^/?_!-_]K2W\4Q:+=^&/BI\
M&_$VJ^%_'/@37VN+?3O$.DR;K#Q)X2UP6S&+4-!\0:<Z7NCZM;?:[42?V#XO
MT&6::STF]']YG[&?[?O[.?[<?@V+Q!\(?%L-MXNL;03>+_A/XDGL].^(O@Z9
M#"DTM]HBW$O]JZ"TMQ"MEXKT*34- NVF2TDO+76(;_2K'QC_ (*&?\$LO@=^
MWUH\.NZG._PS^.FAV$>G^&/B_H>G)J$UQIL#RO%X;\<^'S=:?!XN\/*T\LEB
MYO=.U_0KHK)I.LQ:;-JVC:O_ !__ !X_X)H_M^_L6>-;;6W^&WCS5(- N7U7
MPW\:_P!G[_A)_%6@6;67DXUB'Q%X6LK7Q1X$N8I+CR;?_A+=+\)ZC/)'<2:=
M'=6J?:6C6#>EX_\ #=>GZEZ3M=V?]?TE<_T/JY#QY\0? GPN\+:IXX^)/C+P
MQX!\':+&DNK>*/&&N:;X=T'3UED6*$76JZM<VMG%)<3.D%M"TWFW-Q)';VZ2
M32(C?YV6D?\ !1/_ (*(:%'?>&+/]JW]HV:XU*U-K/::QXZ\4>(=?2'R)9"^
MGWWB";4]>TNX\B1YOMNEW5I=A%CG\_\ <1/&P?!;_@HW^V/KND2ZOX$_:R^/
M>HM,+'2_$/CVU^)?B?1M*-PMO)Y<GC'QS(_ASPY9>5=VLKRWFL:=8PV\\$DC
MQPO&Q?/V3?\ 2_K[NXN3NTE_7]7_  /N/_@L+_P51/[9GB>+X(?!&_N+?]F7
MP+K,6I_VRUK>Z;J7QB\7VD#PQ>)=1L]0@M-0TSPAH)N+JW\(^'[FVM[J]GDG
M\4^(8FOI- TKPK^LO_! C]@77/@MX#UG]KSXI:9)IGC;XT^%K31/A9H%Y;RP
MW^@?"6\O+37+GQ+?I,P"7?Q&O;#0M0T>'[.LMGX6TBPU".\GC\5W%G8^2_\
M!/C_ (( /X1\0^'OB]^W!=Z#KMWH\UCK>@_L_P#AN_36M#35(/*N;8?%?Q'
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MX*I?]$9_X*!_^&[_ &C/_E/1S_W7_5O\_P N^AR?WE_5O\_R[Z?Z,M?QY_\
M!9#_ (*'?MP?#7]K;0OA[X1@\;?LV^!_@QK]MXM^&.HV4D#CXT7<,#V\?Q#U
M/4H1>^'?%?@N\M+V\T:#P!<'4M*L[:YU32O'^EOXBDO=$T/^CG_@G3I'Q T'
M]B']FW1_BIIGC'1OB'I_PYL[?Q9I?Q LM:T[QG9:J-0U%I(?$5CXCBAURVU
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M=/L?5#>_$+^R=:\30PD$W?\ PBNF^)-0C"D?9'8%:.=O9?K^"#DMNTOZ7?\
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G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logo_catalystbiox2.jpg
<TEXT>
begin 644 logo_catalystbiox2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( )8!V ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,*W\;O++%#:6NE^)KJU32M;N9;B:*VM8/#WB6#1M6U"^DWRP:%!K,$ W7;
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MT?X?:'<D22".3Q/<PD#9$P66#14D&6W2@I<ZCLVXB\BT,CK-?0+\;Q[QKEG
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M#5+RV0M]F8U]K5_+1_P2$_: 7X8_M WOPGUR]$'A7XWZ?%I-F9Y8H[:R\?\
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MC_9.\=:A>S^!O@)X%/A+7]:T]I#+9_#3P]JQU#QAX\U.[^PW/V+Q5J7@32_
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MB^T,=Q;:0+1H_ VC7@5#O6QNU^U>)KBWE$AMKO5XK.P*R+(WAZ.\@@ND_1T
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MINIWOC2[L;JZ27PKKNA7$[2VH$)CNY9X5'S)&KY:OZ._^',G_!,[_HUO0_\
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M#OP?_P#5O^":/^"%O_*,_P"!?_8=^,'_ *M_QM1_P72_Y1G_ !T_[#OP?_\
M5O\ @FC_ ((6_P#*,_X%_P#8=^,'_JW_ !M3^W_V[^HOL?\ ;WZ'XH_\%:A!
M\0?^"T?[./@?Q38VVJ>'(KO]E;P'+IDJSO%J'ASQ!\3[G5M5L+M))I%9;N?Q
M7J\#I;);Q-;RH#"UP9[B?^R6OX\/^"BDL4'_  7O_9<GGDCAAA^*?[%4LTTK
MK'%%%'\2/#KR222.0B1H@+.[$*J@LQ !-?V'TUO)^:_!+_,<MH>GZ(*^5OVQ
M?V._A#^W!\'I?@M\9?\ A)+/08_$FB>+M&\0>#+_ $O2_%OAGQ#HAN88M1T*
M^UO1?$>D1R7VD:CK'A_48]0T/489=(UF_$$=MJ LM0L_JFBF1L>!?LO_ +.W
MA+]E#X&^!_@#X$\1>-O%/@_X?QZW;Z!JOQ"U+1M7\5?8]<\1ZOXFDLKW4-!\
M/^&-.FM=.N]9N;/2HXM'MVM-*AL[(O*+99#_ "X_&;_E90T?_LJ_P&_]9H^'
M=?V%U_#;_P %&)OCK;_\%POB-/\ LRK*WQ[B\5? ]OA<L$'A2ZF/B<?LX_##
MR!';^.(YO"4K?9OM.$UV-[$_Q*7\NHEHH^4E^%RHZN7G%ZOY;G]R5%?R7?\
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M=ZS=>%M+U"1IRWAVTB<PMP^L_M+?\'#/[+$\!^)/P]\;?$WP_IEJ7=KCX/>
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M_P#RCN\.?]E7^*'_ *<[&O5_^"WG_*+_ /:<_P"Z+_\ K0OPGKRC_@W_ /\
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MX:XLS7*<L5>KB8X*A.C4H4ZU;E=6=*&(I5O9*I**G.%-PIRJ.=1QYZDY2/\
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JF:HT\/+,,9@LOEC*M&DN6C3KXF&$A6Q"HPM3HNO.HZ-)1I4W&G&,5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ny20009756x1_ex5-1image01.jpg
<TEXT>
begin 644 ny20009756x1_ex5-1image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !* (,# 2(  A$! Q$!_\0
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M/']HE^(^KC4,9^4R>4#UQCS.GX?A3/V<8TN+#Q-JEP VJ7.INL['[V  P_\
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:Z+]PL3]>E%(H"J%4  #  [4M24%%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
